Handbook

HandbookHarrogateInternationalCentre23–26 Mayfocusonchange

Innovationis in ourNAInnovative Scienceto improve the patient experience and reduce the cost of care.Beckman Coulter is one of the leading providers of in vitro diagnostic systems tohospital laboratories throughout the world. We are uniquely positioned as a companywith both research and diagnostic divisions to lead the way in biomedical testing.Our focus in Harrogate will be to share with you some of our innovative science anddemonstrate how this innovation can improve the patient experience and reduce thecost of healthcarePlease join us on stand 18 to experience our technology briefings on Novel Markers orattend our Industry Sponsored Workshop on:Thursday 26th May 10.45 – 11.45Prostate Health Index (phi) – Challenges to the early detection of prostate cancer andthe impact of a new biomarkerEmail: infouk@beckman.comwww.beckmancoulter.co.uk

ContentsIntroductionAcknowledgements 2President’s Message 4Chairman’s Message 6General Information 8Conference Centre Layout 12Map of Harrogate 13Welcome to Harrogate 14Scientific ProgrammeProgramme Summary 17Speaker Profiles 19, 23, 27Monday - Training Day 18Tuesday 20Wednesday 24Thursday 28snippets@Focus 29Satellite MeetingNational Point of Care Co-ordinators Meeting 22PostersACB Poster Prizes 33Tuesday 34Wednesday 38Thursday 41ExhibitionFloorplan 46Index of Participating Companies 47Abstracts of Participating Companies 48Our Thanks toInside Back Cover1Contents

2AcknowledgementsFocus 2011 was organised by the Local Organising Committee under theguidelines provided by the Council of the Association for Clinical Biochemistry.Focus 2011 Local Organising CommitteeSteve GoodallChairEric KilpatrickScientific Programme ChairGwyn McCreanorTreasurerSally SlackSocial Events & PublicityDavid HorneCorporate Members’ RepresentativeMark WeaverCorporate Members’ RepresentativeScientific Programme CommitteeEric KilpatrickChairIan BarlowAshley GarnerBrian KeevilStuart SmellieFocus 2011 | Introducon | AcknowledgementsWith the assistance ofVicki Grant, Stephanie Mair, Colette Craig, Meeting MakersHeidi Cox, Social Events & PublicityIan Hanning, ACB National Meetings SecretaryKathryn Brownbill, ACB National Meetings CommitteeIan Godber, ACB National Meetings CommitteeCharles van Heyningen, Editor, Proceedings of the ACB National MeetingJonathan Berg, Editor, ACB NewsNic Law and the ACB Office StaffACB Executive CommitteeThe Local Organising Committee also wishes to acknowledge the help of:Nikki Beeson, John Williams, Sue Ojakowa and the staff at the Harrogate International CentreISSN No 0959-860XDesigned by John Williams and Nikki BeesonPrinted by Swan Print Ltd, BedfordPublished by PRC Associates Ltd on behalf of the Association for Clinical BiochemistryEdited by Ian Hanning of ACB NewsPhotography supplied by Jonathan Berg

4Focus 2011 | Introducon | WelcomeA message fromJulian BarthPresident of the Association for Clinical BiochemistryOn behalf of the Association for Clinical Biochemistry,I’m delighted to welcome delegates to Harrogate and toFocus 2011. This is the first time that Focus has been held inHarrogate and, indeed, Yorkshire.The theme for this year’s meeting is “Focus on Change” and this isreflected in the scientific programme and the changes in themeeting format. As scientists we are used to change. It is alwaysexpected and has become routine in our profession. We do notalways want change, though, and new ideas presented in theliterature and at scientific meetings frequently divide the scientificcommunity in their opinions. This, in my view, leads to healthydebate, and in itself produces even more new ideas. We anticipatewith relish the debates in the programme. This year, speakers willundoubtedly challenge commonly held beliefs and will providedelegates with many ideas to help guide them through the optimalpaths for laboratory improvement, provision of services andimprovements in the way patients are diagnosed and treated.The new “Hot Topics” plenary session has been carefully chosen tostimulate lively discussion. The whole programme is exciting andvaried and should cater for all tastes. The variability keeps theprogramme fresh and also reminds us that the Association continuesto welcome scientists from a broad spectrum of laboratory specialtiesas its members.The format of the meeting has also changed. We welcome the novel“All Day Breakfast” workshops, changes in the naming and timing ofthe Award Lectures and the increased involvement of the CorporateMembers in their sponsorship of the scientific sessions. Positivefeedback from previous years’ meetings has guided us to keep the“old favourites” in the programme: Attended Poster, Clinical Cases,Audit and Industry Sponsored Workshop sessions.Every year, we expect our profession to face new financial challenges.This year is no exception. Not all talks are focussed on finance, butmany will contain information on how savings can be made. Theproblems facing us in the UK are frequently encountered in othercountries. We welcome our colleagues from outside the UK and lookforward to the interchange of ideas from the wider scientificcommunity.Yorkshire people are well known for speaking their mind, just as wescientists do. They are also well known for their welcome andhospitality, just like the ACB. We hope you enjoy your stay inHarrogate, and the pleasures and new knowledge that Focus 2011will provide.

6Focus 2011 | Introducon | WelcomeA message fromSteve GoodallChairman of the Local Organising CommitteeI am delighted to invite the scientific community to join us inHarrogate for Focus 2011. This is the first time that Focus hasbeen held in Yorkshire, so delegates will be able to look forwardto some brand new experiences. Yorkshire folk are renowned forhaving short arms and long pockets, but do not expect to beshort-changed at Focus. Harrogate, and Focus 2011, have muchto offer, from Bettys Café to cutting-edge scientific advances.The strapline – Focus on Change – is more apt than ever before,particularly for UK delegates, as we anticipate major changes inthe way we deliver pathology services. This does not mean thatthe whole meeting is directed towards this topic. Professor EricKilpatrick and the Scientific Programme Committee have createda very exciting and wide-ranging programme that addresseschanges not only in service provision, but also in scientificknowledge and application.The idea of a new style Focus has been discussed for many years,and the Focus format has changed with the times.Focus 2011 will see a move away from a large commercialexhibition, and will see Corporate Members becoming moreinvolved in sponsoring and supporting the scientific programme.This is a new development that was requested by the companiesand the Local Organising Committee is delighted to be able toincorporate the new ideas. Change indeed.I cannot remember a time when pathology services ever stoodstill. New assays, technologies and methodologies; phone callsfrom clinicians wanting to discuss interesting patients; newknowledge in our understanding of disease processes andtreatment of patients; the way we train our juniors. We live in aworld with changing scenery and this, to me, is what makes ourjobs so varied, interesting and rewarding. It is also whatcontributes to improving patient care.Yorkshire is a varied county. It has spectacular scenery: wildmoors, rugged coastline, holiday resorts, large centres of law,arts and academia. Yorkshire even has its own tongue-in-cheeksong about cannibalism on Ilkla’ (Ilkley) Moor. There arewonderful museums and places to visit. Something for everyone,just like Focus 2011.So we look forward to welcoming you to Harrogate, and wepredict you will have a hugely enjoyable and informativemeeting.

8General informationFocus 2011 | Introducon | General informaonVenueThe venue for Focus 2011 is the HarrogateInternaonal Centre (HIC), King’s Road,Harrogate, North Yorkshire HG1 5LA.Tel: 01423 500 500Website:www.harrogateinternaonalcentre.co.ukTourist InformationHarrogate Tourist Informaon Centre:Tel: 01423 537303Email: c@harrogate.gov.ukWebsite:www.harrogate.gov.uk/immediacy-4660Getting to the VenueHarrogate is ideally situated in the middle ofthe UK, equidistant from both London andEdinburgh. It has good train links, is easilyaccessible by car via the M1 and is only 20minutes away from Leeds Bradford airport.For detailed informaon on travel to thevenue please visit the Harrogate InternaonalCentre website: www.harrogateinternaonalcentre.co.uk/About-Us/Geng-Here.aspxTo get from the airport to Harrogate,the Dales and District 767 bus will drop youoff at the bus staon, then it is just ashort walk to the Harrogate InternaonalCentre.The closest bus stop to the HarrogateInternaonal Centre is Cheltenham Crescent.More informaon can be found at:www.dalesanddistrict.co.uk orTel: 01677 425203.Harrogate Internaonal Centre is easilyaccessible by train. When at Leeds/Yorkthere is a simple change to a Harrogatebound train. These run every half hour(through the week) with an average journeyme of 30-40 mins.For more informaon on trains to and fromHarrogate please call Naonal Rail EnquiriesTel: 08457 48 49 50 or www.naonalrail.co.ukDriving to Harrogate Internaonal Centre:There are 210 car parking spaces at theHarrogate Internaonal Centre, with afurther 1,200 at the nearby Jubilee andVictoria car parks.

Arrival/RegistrationMonday registraon will take place in theKing’s Suite Entrance. For the remainder ofthe week, the Registraon Desk will belocated in the main recepon of theHarrogate Internaonal Centre and will beopen from:08.00-18.00 on Monday 23rd May,08.00-17.00 on Tuesday 24th and Wednesday25th May, and from 08.15-16.00 on Thursday26th May.HotelsFor locaons, see map on page 13.Any queries regarding accommodaonbookings made through Focus 2011Secretariat should be addressed directly toMeeng Makers. At the me of booking alldelegates were required to provide creditcard details to secure their booking. Thesedetails have been forwarded to the hotel, butpayment will not have been taken. Delegatesmust sele their own accounts on departurefrom their hotel. In the event of acancellaon of a hotel booking received aerthe 25th March, the hotel will deduct fromyour credit card an amount equal to theduraon of the stay booked.Resident delegates must comply with thecheck-out mes of individual hotels andensure that all charges are cleared beforedeparture. Those needing to leave luggage onthe first or last day can do so at the maincloakroom of the Harrogate InternaonalCentre.Hotel Contact DetailsHoliday InnKings Road, Harrogate HG1 XXTel: 01423 849 988Hotel du VinProspect Place, Harrogate HG1 1XXTel: 01423 856 800Majestic HotelRipon Road, Harrogate HG1 2HUTel: 01423 700 300Old SwanSwan Road, Harrogate HG1 2SRTel: 01423 500055Conference InformationAny urgent messages received for delegateswill be displayed on a noce board in theregistraon area at Harrogate InternaonalCentre.Scientific SessionsPlease refer to the programme on pages17-28 for full details.All Day Breakfast WorkshopsThese will take place in the Queen’s Suiteof the Harrogate Internaonal Centre from08.45-16.40 on Tuesday 24th May and08.45-15.55 on Wednesday 25th May.PostersPosters will be displayed in the ExhibionHall. Presenng authors are required to bepresent from 13.00-13.45. Posters should bemounted between 08.00-09.00 and removedby the following mes to prevent disposal:Tuesday - 17.00Wednesday - 17.00Thursday - 14.00Focus 2011 | Introducon | General informaon9

10Annual General MeetingsThese will be held on Monday 23rd Mayand will be preceded by an informal drinksrecepon which will take place in theKing’s Suite from 16.30-17.15 before themeengs commence.The AGM of the Federaon of ClinicalSciensts will be from 17.15-17.45, followedby the AGM of the Associaon for ClinicalBiochemistry from 18.00-18.45.ExhibitionThe Focus Exhibion opening mes are asfollows:Tuesday 24th May 10.00-19.00Wednesday 25th May 10.00-17.30Thursday 26th May 10.00-14.30WiFi AccessThe Harrogate Internaonal Centre has WiFiaccess available. There is a charge for thisservice and delegates are required topurchase vouchers from the HarrogateInternaonal Centre Main recepon desk orthe Hall Q support office. The cost is £4.00for 60 minutes.CateringRefreshments and lunch will be provided atthe catering points in the Exhibion Hall,Hall Q. Coffee and Tea will be provided from10.45-11.45 and 14.00-15.15 on Tuesday andWednesday and from 10.45-11.45 onThursday. Lunch will be provided from12.30-14.00 on Tuesday, Wednesday andThursday.Focus 2011 | Introducon | General informaon

Public TelephonesAt present there are no public telephonesin The Harrogate Internaonal Centre.The nearest public telephone is in theHoliday Inn Hotel.CloakroomCloakrooms are available in the entrance ofthe Harrogate Internaonal Centre.CashpointThe nearest cashpoint is in the HarrogateInternaonal Centre outside Hall M - there isno charge for using this machine forwithdrawing cash. If for some reason it isunavailable then there are cashpoints onParliament Street and outside all the majorbanks.SecurityDelegates are reminded to wear their Focusbadges at all mes. Entry to the ScienficSymposia will be restricted to personswearing appropriate badges. Those wearingExhibion Visitor badges will only beallowed into the Focus Exhibion.Mobile Phones and PagersAs a courtesy to speakers and other delegates,mobile phones and pagers must be switchedoff, or set to a non-audible alert, beforeentering lecture theatres or meeng room.Focus 2011 | Introducon | General informaonAudio Visual ServiceThe speakers’ preview room will be in themain recepon area behind the RegistraonDesk. Please ask registraon staff forguidance on accessing the area.CPDThe meeng is registered for CPD with theRoyal College of Pathologists and theInstute of Biomedical Science. Cerficates ofAendance can be collected from theRegistraon Desk.Delegates are reminded to sign in eachmorning. Sign in sheets will be located inthe registraon area.SmokingFocus 2011 is a non-smoking event.11

12Conference Centre LayoutFocus 2011 | Introducon | Maps and Plans

Focus 2011 | Introducon | Maps and Plans13

14Focus 2011 | Introducon | Welcome to HarrogateWelcome to HarrogateDeliciously Yorkshire . . .This charming town on the edge of theYorkshire Dales boasts characteristicarchitecture, grand boulevards,café-lined streets, elegant boutiquesand flower-filled green spaces.Harrogate is Britain’s original spa town.The town’s first well was discovered in 1571by William Slingsby who christened thetown “The English Spa”.Famous for its sulphur and iron rich waters,Harrogate water gained popularity when an18th century physician called Timothy Bightclaimed that the spa water had healingproperties. It was claimed that the watersof Harrogate could cure gout, rheumatismand nervous tension. Although the healingproperties of Harrogate water have neverbeen proven in randomised controlledtrials, over 50,000,000 bottles of HarrogateSpring Water are sold throughout Britainevery year!Nowhere serves a cup of tea like Bettys TeaRooms of Harrogate. Established in 1919it is still serving the finest cuppa withdelicious Yorkshire and continentalconfections. Bettys is nestled amongstHarrogate’s famous 19th century TurkishBaths, unique shops and over 100cosmopolitan restaurants and bars. All justa few minutes walk away from yourconference centre and accommodation.For those of you choosing to stay andexplore Harrogate before or after theconference you are not short of options:• Browse antiques and unusual gifts inthe stylish Montpellier Quarter.• De-stress and relax in the steam andhot rooms of the preserved Turkish SpaBaths, built in 1897 and restored in2004.• Enjoy a stroll around the town, admiringits award winning floral displays enroute. The town boasts 200 acres ofgreen lawns which surround the town.

• Visit the impressive Royal HorticulturalSociety Gardens at Harlow Carr.• Put on your hiking boots and explore.Walking in this area of North Yorkshireis fantastic. Brimham Rocks are anamazing collection of weird andwonderful rock formations, whilstMalham Cove is a unique naturalamphitheatre made up of curvedlimestone cliffs. Both definitely wortha visit with your cameras at the ready.• Visit the nearby Black Sheep Brewery fora tour. In a world of ever increasingbland, mass-produced beer these boysare serious about their traditional ale!You are not short of options when lookingto explore this region. As a local once said“If it’s artside Yorkshire, it int w’th bl*ddyvisitin!”. We hope you enjoy all that thisfantastic area has to offer.It’s not so grim up north after all!Focus 2011 | Introducon | Welcome to Harrogate15

Summary ProgrammeMonday 23rd May09.30-16.30 Training Day17.15-17.45 AGM of the Federation of Clinical Scientists18.00-18.45 AGM of the Association for Clinical BiochemistryTuesday 24th May08.45-10.45 Parallel Sessions:New TechnologiesPoint of Care Testing08.45-11.15 EBLM Workshop10.45-11.45 Break and Industry Sponsored Workshops11.45-12.30 ACB Foundation Award Lecture12.30-14.00 Lunch and Exhibition13.00-13.45 Attended Poster Session14.00-14.45 RCPath Flynn Lecture14.45-15.15 Break15.15-17.15 Parallel Sessions:Blood Sciences LaboratoryAuditThe Novel Application of POC DiagnosticsWednesday 25th May08.45-10.45 Parallel Sessions:Clinical Chemistry and the CoronerCancer: Meeting the Needs of the Patient10.45-11.45 Break and Industry Sponsored Workshops11.45-12.30 ACB International Lecture12.30-14.00 Lunch and Exhibition13.00-13.45 Attended Poster Session and Hot Topic Posters14.00-14.45 Professors’ Prize Lecture14.45-15.15 Break15.15-17.15 Parallel Sessions:Clinical Practice SectionResearch in Clinical BiochemistryACB Medal AwardsThursday 26th May08.45-10.45 Parallel Sessions:Clinical CasesClinical Chemistry in the Age of Austerity10.45-11.45 Break and Industry Sponsored Workshops11.45-12.30 AACC Transatlantic Award Lecture12.30-14.00 Lunch and Exhibition13.00-13.45 Attended Poster Session14.00-16.00 Hot Topics16.00 Closing Remarks and Presentation of AwardsFocus 2011 | Programme | Summary17

18Sunday 22nd May19.30-22.30 Trainees’ Dinner RESTAURANT BAR & GRILLTrainees are invited to join members of the Education Committee and Training Dayspeakers for dinner at the Restaurant Bar & Grill, 46-48 Parliament Street,Harrogate HG1 2RL.Monday 23rd MayTraining Day09.30-12.30 Clinical Cases KING’S SUITELed by Dr Danielle FreedmanDr Freedman will be bringing her clinical knowledge and experience to this interactivesession on clinical cases. This session will be useful for Trainees preparing for theirFRCPath exams.12.30-13.30 Lunch KING’S SUITEFocus 2011 | Programme | Sunday & Monday13.30-16.30 Transforming Pathology Services KING’S SUITELed by Alan ThorneThe NHS is facing a challenging future with an increasing demand for services but withlimited resources. Alan Thorne will bring his experience of change management andstaff engagement to the session on Transforming Pathology.16.30-18.45 Reception and Annual General Meetings KING’S SUITEAn informal drinks reception will precede the AGMs.17.15-17.45 AGM of the Federation of Clinical Scientists18.00-18.45 AGM of the Association for Clinical Biochemistry19.30-late Corporate Members’ Evening THE ROYAL HALLThe Corporate Members' Evening will be held in The Royal Hall, a stunning EdwardianTheatre built in 1903. Restored to its original magnificence in 2008, this ‘palace ofglittering gold’ has to be the ultimate backdrop for a memorable evening. The RoyalHall is situated within the conference centre and is a short walk from your conferencehotel.

Plenary Speaker Profiles – TuesdayDr Ian WatsonIan Watson is Clinical Director and Consultant Clinical Biochemist andToxicologist at University Hospital Aintree, Liverpool, with specialistclinical interests in Analytical Toxicology, Neurobiochemistry, and POCT.He is President of the European Federation of Clinical Chemistry andLaboratory Medicine, a Past-President of the Association for ClinicalBiochemistry and of the International Association for Therapeutic DrugMonitoring and Clinical Toxicology.Toxicology has had a very different spectrum of analytical and clinicalchallenges over 40 years ago and having been a part of some of the actionover this time he has published over 100 peer-reviewed publications,3 books and several book chapters, mainly on toxicology-related topics.He is Chair of the Heathcontrol EQA Scheme for Drug Assays; has led in theproduction of UK National Guidelines on the Laboratory and Poisoning, andin their current revision. He has also helped develop national guidance onthe laboratory detection of intra-cranial bleed and adoption of HbA1cstandardisation.He remains an active drummer!Dr Danielle FreedmanDanielle Freedman MB BS, FRCPath, EurClinChem is a Consultant ChemicalPathologist and Associate Physician in Clinical Endocrinology, ClinicalDirector for Pathology and Anticoagulation, Luton and Dunstable NHSFoundation Trust. In addition, she was the Hospital Medical Director fromOctober 2005 until December 2010.She trained in Medicine at the Royal Free Hospital School of Medicine,London University and undertook further training in Clinical Biochemistryand Endocrinology both at the Royal Free Hospital and the MiddlesexHospital, London.Nationally, she is an elected Vice President of the Royal College ofPathologists (RCPath) and sits on the RCPath Executive and Council. She isChair of the RCPath Speciality Advisory Committee for Clinical Biochemistryand is a Member of the Department of Health National Pathology FuturesGroup and Pathology Messaging and Interoperability Board. She is a CPANational Assessor and Member of the UK NEQAS Clinical ChemistryAdvisory Group for Interpretative Comments.Her main interests include clinical endocrinology, point of care testing and,importantly, the role of the laboratory/clinician interface with regard topatient safety and patient outcome.She has over 100 publications in peer review journals including Lancet,New England Journal of Medicine, JAMA and Annals of Clinical Biochemistryin her areas of interest.She is a frequently invited speaker both nationally and internationally onthe above topics. She won the ‘Outstanding Speaker’ Award in 2009 fromthe American Association of Clinical Chemistry (AACC) and is a Member ofthe AACC Annual Meeting Organising Committee for 2011.Focus 2011 | Speaker Profiles | Tuesday19

20Tuesday 24th May08.45-10.45 Parallel SessionsNew TechnologiesHALL DChair: Mr Brian Keevil, Manchester08.45-09.15The use of accurate mass in LC/MSdeterminationsDr Mike Morris, Manchester09.15-09.45Engineering femtomolar affinity antibodiesfor improved assay sensitivityDr Dagang Huang, Illinois, USA09.45-10.15Nanoscale diagnostics: probing proteinstructure and function at the singlemolecule levelProf John Ryan, Oxford10.15-10.45Future directions for biosensorsProf John Pickup, LondonPoint of Care TestingMAIN AUDITORIUMChair: Mr Ian Barlow, Scunthorpe08.45-09.15UKAS accreditation for point of care testingDr Jane Beaumont, London09.15-09.45Straight to the point: iPOCT first to gainUK accreditation for point of care testingMs Claire Pridige, Skipton09.45-10.15Blunders and how to avoid themMrs Lynda Petley, Frimley Park10.15-10.45Point of care testing in thedevelopment of primary careProf Chris Price, OxfordSponsored byDiagnosticsFocus 2011 | Programme | Tuesday08.45-11.15 EBLM Workshop KING’S SUITEEnhance your EBLM skills at this workshop organised by the ACB Education and ScientificCommittees. The workshop aims to help participants develop EBLM skills and will includethe following sessions:Formulating the QuestionAcquiring the EvidenceAppraising the EvidenceWorking in groups, under the guidance of a mentor, a number of topical issues will becovered.10.45-11.45 Break and Industry Sponsored WorkshopsOrtho Clinical DiagnosticsWatersBlood Sciences Laboratory inthe Small or Specialist Hospital:Is it a Worthwhile Approach?QUEEN’S SUITE 2Chair: Peter Clements, Ortho ClinicalDiagnosticsDavid Wells, Great Ormond Street HospitalThe principle of a Blood Sciences Laboratoryin the large high throughput routinelaboratory is an accepted model for producingefficiencies and financial benefits. Applyingthis approach on a smaller scale tomainstream testing at Great Ormond StreetHospital has delivered unique benefits for theprovision of specialist testing services;justifying the project costs.Advances in Clinical andForensic Mass SpectrometryQUEEN’S SUITE 6Chair: tbcUse of the novel acquisition modeMSe for comprehensive toxicologicalscreeningDr Mike Morris, ManchesterFollowed by Waters latest technology update.

11.45-12.30 ACB Foundation Award Lecture MAIN AUDITORIUMChair: Dr Julian Barth, LeedsIlluminating facets of analytical toxicology:past, present and futureDr Ian Watson, AintreeSponsored by Diagnostics12.30-14.00 Lunch and Exhibition HALL Q13.00-13.45 Attended Poster Session HALL Q14.00-14.45 Flynn Lecture MAIN AUDITORIUMChair: Dr Tim Wreghitt, CambridgePOCT: dangerous indulgence or essential to quality care?Dr Danielle Freedman, Luton14.45-15.15 Break HALL Q15.15-17.15 Parallel SessionsBlood SciencesLaboratoryMAIN AUDITORIUMChair: Mr Ian Hanning, Hull15.15-15.45Haematinics in the BloodSciences laboratoryDr Mike Galloway, Sunderland15.45-16.15Immunology in the BloodSciences laboratoryDr Jo Sheldon, London16.15-16.35Microbiology in the BloodSciences laboratoryDr Kate Templeton, Edinburgh16.35-17.15The Blood Sciences laboratory:the agony and the ecstasyDr Jean Wardell, Doncasterand Dr Eileen Marks, LiverpoolSponsored byDiagnosticsAuditQUEEN’S SUITE 2Chair: Mrs Annette Thomas,Cardiff15.15-15.55National AuditsAudit of internal qualitycontrol pracce and processesDr David Housley, LutonMs Teresa Teale, WinchesterPresentaons selectedfrom submied abstracts15.55-16.15Dr Afaf Hassan, Manchester(see poster T68)16.15-16.35Mr Edward Hinchliffe,Manchester (see poster 8)16.35-16.55Dr Lucy Hawkins, TunbridgeWells (see poster T69)16.55-17.15Ms Ayesha Azam, Dudley(see poster 9)The Novel Applicationof POC DiagnosticsHALL DChair: tbc15.15-15.55A fully integrated approachto point of care testingDr Devi Nair, London15.55-16.35Home monitoring ofheart failureProf Henry Dargie, Glasgow16.35-16.45Chest pain assessment usinga panel of POC biomarkersDr Sanjay Ramamoorthy,SouthamptonHosted byFocus 2011 | Programme | TuesdayAll Day Breakfast SessionsQUEEN’S SUITE1: 08.45-09.25 Trial statistics for dummies Dr Rick Jones, Leeds SUITE 42: 09.30-10.10 Urinary C-peptide for diagnosing MODY Mr Tim McDonald, Exeter SUITE 83: 10.15-10.55 Introducing new analysers or techniques into the medical laboratory:A practical guide to acceptance testing Dr Robert Hill, Sheffield SUITE 44: 15.15-15.55 HbA1c: two years on from standardisation Prof Eric Kilpatrick, Hull SUITE 85: 16.00-16.40 Pharmacogenomics of chemotherapy susceptibility Prof Ian Cree, Portsmouth SUITE 417.15-19.00 Reception in the Exhibition HALL QThere will be an extended drinks reception and buffet in the exhibition areaimmediately after the end of the day’s scientific programme giving delegatesthe opportunity to engage with our corporate members and network withcolleagues in a relaxed atmosphere.21.00-late Focus Fringe MONTEY’S ROCK CAFÉJoin us at Montey’s Rock Café, 3 The Ginnel, Harrogate HG1 2RB.21

22Tuesday 24th MaySatellite MeetingNational Point of Care TestingCo-ordinators Meeting08.45-10.45 Point of Care Testing* MAIN AUDITORIUMChair: Mr Ian Barlow, Scunthorpe08.45-09.15UKAS accreditation for point of care testingDr Jane Beaumont, London09.15-09.45Straight to the point: iPOCT first to gain UK accreditation for point of care testingMs Claire Pridige, Skipton09.45-10.15Blunders and how to avoid themMrs Lynda Petley, Frimley Park10.15-10.45Point of care testing in the development of primary careProf Chris Price, OxfordSponsored byDiagnosticsFocus 2011 | Satellite Meeng | Tuesday11.45-12.30 Morning Session QUEEN’S SUITE 1The role of the portable blood gas analyser in the communityMrs Sandra Hoyle, Manchester12.30-14.00 Lunch & Exhibition HALLS 1 & 214.00-14.45 Flynn Lecture* MAIN AUDITORIUMChair: Dr Tim Wreghitt, CambridgePOCT: dangerous indulgence or essential to quality care?Dr Danielle Freedman, Luton15.15-17.15 The Novel Application of POC Diagnostics* HALL DChair: tbc15.15-15.55A fully integrated approach to point of care testingDr Devi Nair, London15.55-16.35Home monitoring of heart failureProf Henry Dargie, Glasgow16.35-16.45Chest pain assessment using a panel of POC biomarkersHosted byDr Sanjay Ramamoorthy, Southampton*ACB sessions

Plenary Speaker Profile – WednesdayProf Mario PlebaniMario Plebani obtained his medical degree summa cum laude from theMedical School of University of Padova in 1975. He completedspecialisaon in Laboratory Medicine (1978), then Gastroenterology(1983), at the same University. In 1991 he was appointed Head of theClinical Laboratory of the University-Hospital in Padova and in 2001 Chairof the Department of Laboratory Medicine. In 2003 he was appointedFull Professor of Clinical Chemistry and Clinical Molecular Biology at theMedical School.Currently, he is Director of the Postgraduate School in Clinical Biochemistryand President of the course for Medical Technologists. He is a Fellow ofRCPath and a Member of the ACB. He is Past-President of the InternaonalSociety of Enzymology (ISE) and of the Italian Society of ClinicalBiochemistry and Molecular Clinical Biology. He is President of the ItalianFederaon of Scienfic Sociees of Laboratory Medicine (FISMeLAB).He has published 700 original papers and is a recipient of a number ofnaonal and internaonal Awards, including the 2008 AACC Award forOutstanding Clinical Laboratory Contribuons to Paent Safety. He is Editorin Chief of Clinical Chemistry and Laboratory Medicine (CCLM), andAssociate Editor of other journals.Dr Rossa ChiuAer graduang from the University of Queensland, Australia, in 1997with First Class Honours in Bachelor of Medicine and Bachelor of Surgery,Dr Rossa Chiu specialised in Chemical Pathology. She received postgraduatetraining in research and was awarded Doctor of Philosophy by The ChineseUniversity of Hong Kong in 2004.Dr Chiu joined the Department of Chemical Pathology, The ChineseUniversity of Hong Kong in 1999 as Assistant Professor, became AssociateProfessor in 2004 and then Senior Lecturer, her current posion, in 2008.She is also an Honorary Consultant at the New Territories East Cluster ofHospitals, Hong Kong.Dr Chiu’s main research interests include the development of non-invasiveprenatal diagnosc approaches, novel molecular diagnosc strategies andinnovave applicaons of molecular analysis tools. She was the first todevelop approaches to apply cell-free fetal DNA analysis in maternalplasma for the non-invasive prenatal diagnosis of autosomal recessivediseases. Recently, she was the first to perform a large scale study todemonstrate the effecveness of massively parallel sequencing as a clinicaldiagnosc tool for non-invasive prenatal diagnosis of Down’s syndrome.To date, Dr Chiu has published over 100 peer-reviewed research arcles,15 books or monographs, delivered over 30 invited presentaons and has19 granted patents or patent applicaons. Dr Chiu has been awarded theIFCC Roche Young Invesgator Award in 2011, plus other awards.She is Past President of the Hong Kong Society of Clinical Chemistry.Focus 2011 | Speaker Profile | Wednesday23

24Wednesday 25th May08.45-10.45 Parallel SessionsClinical Chemistry andthe CoronerMAIN AUDITORIUMChair: Dr Ian Watson, Aintree08.45-09.15Forensic work: legal aspects/requiredstandards and the implications for NHSClinical Chemistry laboratoriesMr Andrew Rennison, Birmingham09.15-09.45The laboratory investigation offorensic toxicology casesDr Stephen George, Birmingham09.45-10.15Forensic/Morbid casesDr Nigel Cooper, Newcastle10.15-10.45Coronial work: future developmentsDr Stephen Morley, SheffieldCancer: Meeting the Needsof the PatientHALL DChair: Dr Margaret McDonnell, Belfast08.45-09.15Cancer in the UKMs Louise Jones, Cancer Research UK09.15-09.45The laboratory and cancer: the role ofbiomarkers in the diagnosis, monitoringand treatment of cancerDr Cathie Sturgeon, Edinburgh09.45-10.15Ovarian cancerProf Ian Jacobs, London10.15-10.45Lung cancerDr Petra Stieber, Munich, GermanyHosted byFocus 2011 | Programme | Wednesday10.45-11.45 Break and Industry Sponsored Workshops QUEEN’S SUITEImmunodiagnostic Systems (IDS) Ltd Sebia UK LtdClinical Application of Bone Markers QUEEN’S SUITE 6QUEEN’S SUITE 2Chair: tbcChair: Dr Richard Eastell, SheffieldMyeloma, The Patient’s PerspectiveProf Erik Fink Eriksen, OsloMr Eric Low, Chief Executive, Myeloma UKNew Applications for the SebiaCapillarys2 Flex PiercingMr Martin Hurl, Sebia UK Ltd11.45-12.30 ACB International Lecture MAIN AUDITORIUMChair: Dr Julian Barth, LeedsAn unfinished journey: the role of laboratory medicinein patient safetyProf Mario Plebani, Padova, Italy12.30-14.00 Lunch and Exhibition HALL Q13.00-13.45 Attended Poster Session and Hot Topic Posters HALL Q

14.00-14.45 Professors’ Prize Lecture MAIN AUDITORIUMChair: Prof Gordon Ferns, KeeleNon-invasive prenatal diagnosis empowered by massively parallel sequencingDr Rossa Chiu, Hong Kong14.45-15.15 Break HALL Q15.15-17.15 Parallel SessionsClinical Practice SectionHALL DChair: Dr Stuart Smellie, Bishop Auckland15.15-16.15Head over the parapet: suggestions forharmonising laboratory profile contentDr Stuart Smellie, Bishop Auckland16.15-17.15The Great Debate: Genetic screening forfamilial hypercholesterolaemia is a priorityFor: Dr Dermot Neely,Newcastle-upon-TyneAgainst: Prof Jonathan Kay, OxfordResearch in Clinical BiochemistryMAIN AUDITORIUMChair: Dr Ashley Garner, Leeds15.15-15.45Current research activity in clinicalbiochemistry laboratories: what does thefuture hold for biomarker researchprogrammes?Miss Sophie Hepburn, Leeds15.45-16.15Funding opportunities for clinicalbiochemistry researchProf Lindsay Turnbull, Hull16.15-16.45Turning ideas into funded researchProf Ian Young, Belfast16.45-17.15Doing meaningful research withlimited resourceProf Eric Kilpatrick, HullFocus 2011 | Programme | Wednesday25

2615.15-17.15 ACB Medal Awards QUEEN’S SUITE 2Chair: Dr Julian Barth, President, Association for Clinical Biochemistry15.15-15.35Evaluation of a kisspeptin assay as a screening tool for pre-eclampsiaJames Logie, Wishaw15.35-15.55Glycosylation of IgG paraproteins: a potential marker of malignancyJessica Schroeder, Redditch15.55-16.15Single nucleotide polymorphisms in the tyrosinase gene and their associationwith the risk of and severity of multiple sclerosisNaomi Rankin, Stoke-on-Trent16.15-16.35Development of an assay for the genetic diagnosis of 17β-hydroxysteroiddehydrogenase type 3 deficiencyGhazaleh Esmaeil Pourmahram, Hertfordshire16.35-16.55Real-time PCR genotyping of four SNPs associated with warfarin sensitivityand their frequency in an anticoagulated patient groupFiona Davidson, Bristol16.55-17.15Manipulation of the active site of human glycolate oxidase to assess therole of long-chain hydroxy-acid oxidase in glyoxylate metabolismNick Unsworth, LondonSponsored byFocus 2011 | Programme | WednesdayAll Day Breakfast SessionsQUEEN’S SUITE6: 08.45-09.25 Hypoglycaemia Dr Tim Lang, Durham SUITE 47: 09.30-10.10 Treating diabetes in the 10s Dr Paul Peter, Bishop Auckland SUITE 88: 10.15-10.55 Complex dyslipidaemias Dr Tony Wierzbicki, London SUITE 49: 15.15-15.55 Adding value: a consultant resource pack Dr Mike Bosomworth, Leeds SUITE 819.30-23.30 Conference Dinner THE ROYAL HALLThe conference dinner will be held in the Royal Hall which is part of the HarrogateInternational Centre Complex and is only a short walk from all the conference hotels.Pre-dinner drinks will be followed by dinner and entertainment. To acknowledge thefact that we are lucky enough to spend the evening in the Royal Hall in the year ofthe Royal Wedding, we invite you to dress for a Royal Party.

Plenary Speaker Profile – ThursdayProf Robin FelderProfessor Felder is Associate Director of Clinical Chemistry, the formerDirector of the Medical Automation Research Center, and a Professor ofPathology at the University of Virginia in Charlottesville, Virginia.His affiliation with professional organizations includes Past President andFounder of the Association for Laboratory Automation and FoundingEditor of its journal, Fellow of the Council for High Blood PressureResearch (a council of the American Heart Association) and a Fellow of theNational Association for Clinical Biochemists.He has published over 260 research papers, has been awarded 12 patents,and has presented over 140 lectures in 15 countries. He has receivednumerous awards including the International Engelberger Award forRobotics in 2009, the Research Awards from the American Association forClinical Chemistry and the National Academy of Clinical Biochemistry in2010, and one of his inventions was named a Top 10 Technology byThe Scientist in 2009.In addition to his academic career, Professor Felder has co-founded 9private ventures spun out from the University of Virginia, includingwww.medicalautomation.com, www.globalcellsolutions.com,www.hypogen.com, www.labautomation.org,www.medicalautomation.org, www.wellawaresystems.com, BioPhile Inc,Ibetics LLC, and Medical Robotics LLC.Focus 2011 | Speaker Profile | Thursday27

28Thursday 26th May08.45-10.45 Parallel SessionsClinical CasesMAIN AUDITORIUMChair: Dr Danielle Freedman, LutonCases byDr Danielle Freedman, LutonMr Mike Hallworth, ShrewsburyProf Jonathan Kay, OxfordProf Eric Kilpatrick, HullMrs Ruth Lapworth, AshfordClinical Chemistry in the Age of AusterityHALL DChair: Dr Martin Myers, Preston08.45-09.25Pathology transformation: the developing landscapeDr Ian Barnes, Leeds09.25-10.05Pathology re-engineeringMr Peter Wisher, Lincoln10.05-10.45Pathology: the organisational challengeMr Phil Hudson, Manchester10.45-11.45 Break and Industry Sponsored WorkshopsFocus 2011 | Programme | ThursdayAlpha Laboratories LtdFocus on AKI with NGAL & LiverFibrosis with Hyaluronic AcidQUEEN’S SUITE 2Chair: Dr Jean Wardell, DoncasterThe Use of HA in a Clinical SettingProf PC Hayes, Professor of Hepatology,Liver Unit, Royal Infirmary of EdinburghNGAL in Clinical PracticeDr Marlies Ostermann, ConsultantNephrologist, Guy’s Hospital, LondonBeckman Coulter UK LtdProstate Health IndexQUEEN’S SUITE 6Chair: Mark Stearman, Beckman CoulterUK LtdChallenges to the early detection ofprostate cancer and the impact of anew biomarker11.45-12.30 AACC Transatlantic Award Lecture MAIN AUDITORIUMChair: Dr Mike Thomas, LondonLaboratory automation; the next generationProf Robin Felder, Charlottesville, USA12.30-14.00 Lunch and Exhibition HALL Q13.00-13.45 Attended Poster Session HALL Q14.00-16.00 Hot Topics MAIN AUDITORIUMChair: Prof Eric Kilpatrick, HullHbA1c for diabetes diagnosis: for better or for worse?Prof W Garry John, Norfolk & NorwichVitamin DProf William Fraser, NorwichHigh sensitivity troponins: how should we be using them?Dr Paul Collinson, London16.00 Closing Remarks and Presentation of Awards MAIN AUDITORIUMChair: Dr Julian Barth, President, Association for Clinical Biochemistry

snippets@Focussnippets@Focus will give all delegates the opportunity to engage with a wide rangeof scientific, managerial and work-related topics. The snippets@Focus presentationarea is located Hall Q. Sessions will take place each day during the breaks and areopen to all. The day-to-day schedule is given below.Tuesday 24th May11.00-11.15 T1 Automaon of assays in the clinical laboratory using aGERSTEL mul-purpose sampler (MPS)11.25-11.40 T2 Cliquid and iMethods - LC-MS/MS soluons for clinical research12.40-12.55 T3 Introducon to heavy-light chain (Hevylite) assays and theirclinical applicaons13.05-13.20 T4 An introducon to the LIAISON XL®13.30-13.45 T5 What is the future for HbA1c tesng?14.55-15.10 T6 Analysis of Vitamin D metabolites by tandem mass spectrometryand online extraconWednesday 25th May11.00-11.15 W1 What is the future for HbA1c tesng?11.25-11.40 W2 Introducon to heavy-light chain (Hevylite) assays and theirclinical applicaons12.40-12.55 W3 Hypogonadism, insulin resistance and cardiovascular risk13.05-13.20 W4 A quick and easy ‘new generaon’ test for colorectal cancer13.30-13.45 W5 Liquid chromatograhy-tandem mass spectrometry soluonsfor steroid analysisFocus 2011 | Exhibion | snippets@FocusThursday 26th May11.25-11.40 Th2 Agilent Technologies Clinical Applicaons Including1,25-Dihydroxyvitamin D 3 and D 212.40-12.55 Th3 Introducon to heavy-light chain (Hevylite) assays and theirclinical applicaons13.30-13.45 Th5 Improving transparency and tracking of pathology samplesand clinical trials29

30Tuesday 24th May11.00-11.15 Anatune LtdT1: Automaon of assays in the clinical laboratory using a GERSTELmul-purpose sampler (MPS)Bob GreenPresented are two simple to operate automated assays. The analysis of Vitamin Din blood serum and the analysis of selected immunosuppressants, tacrolimus,sirolimus and cyclosporin A in whole blood. Experimental results being presentedinclude serum and whole blood calibraon curves and the analysis of commerciallyavailable quality control samples.11.25-11.40 AB Sciex UK LtdT2: Cliquid and iMethods - LC-MS/MS soluons for clinical researchDan Leigh, Senior Applicaon Specialist12.40-12.55 The Binding SiteT3: Introducon to heavy-light chain (Hevylite) assays and their clinicalapplicaonsAlison Levoguer, Scienfic Affairs Manager, The Binding SiteThis talk will focus on the development, analycal validaon and inial clinical datapublished on the novel IgG, IgA and IgM heavy-light chain assays.Focus 2011 | Exhibion | snippets@Focus13.05-13.20 DiaSorinT4: An introducon to the LIAISON XL®Darren TomlinsonPlease join us for a brief introducon to the LIAISON XL® our new,high throughput, random access immunoassay analyser. We took what made the LIAISON®so successful and combined that with cung-edge soware and hardware design, producingthe first single immunoassay plaorm allowing consolidaon of specialist and roune work.13.30-13.45 Menarini Diagnoscs LtdT5: What is the future for HbA1c tesng?Stuart Chisnall, Product Manager, Menarini DiagnoscsWHO have recently recommended that HbA1c is used to diagnose diabecs.What methods are available to detect HbA1c and what are the differences between them?Which method should a laboratory use to measure HbA1c? Is there an idealinstrument?14.55-15.10 AB Sciex UK LtdT6: Analysis of Vitamin D metabolites by tandem mass spectrometryand online extraconDan Leigh, Senior Applicaon SpecialistIt is of increasing interest in the clinical research laboratory to consider tandem massspectrometry as an analycal technique for the analysis of steroids. We present here asummary of soluons offered by AB Sciex for these somemes challenging applicaons.

Wednesday 25th May11.00-11.15 Menarini Diagnoscs LtdW1: What is the future for HbA1c tesng?Stuart Chisnall, Product Manager, Menarini DiagnoscsWHO have recently recommended that HbA1c is used to diagnose diabecs.What methods are available to detect HbA1c and what are the differences between them?Which method should a laboratory use to measure HbA1c? Is there an ideal instrument?11.25-11.40 The Binding SiteW2: Introducon to heavy-light chain (Hevylite) assays and their clinicalapplicaonsAlison Levoguer, Scienfic Affairs Manager, The Binding SiteThis talk will focus on the development, analycal validaon and inial clinical datapublished on the novel IgG, IgA and IgM heavy-light chain assays.12.40-12.55 Bayer HealthCareW3: Hypogonadism, insulin resistance and cardiovascular riskDr R Ajjan, Senior Lecturer/Consultant in Diabetes and Endocrinology,St James Hospital, LeedsCardiovascular disease remains the main cause of mortality in individuals with diabetes.Insulin resistance represents a key mechanism in the pathogenesis of type 2 diabetes andalso plays a central role in vascular pathology. In this presentaon, the evidence linkinghypogonadism in men to insulin resistance will be presented, data on testosterone levels indiabetes reviewed and the effects of testosterone replacement therapy on cardiovascularrisk discussed.13.05-13.20 ScheBo® • Biotech UK LtdW4: A quick and easy ‘new generaon’ test for colorectal cancerIvor Smith, Managing Director, ScheBo® • Biotech UK LtdThe launch of the new ScheBo® • M2-PK Quick ‘rapid test’ brings benefits for clinicalbiochemists, paents and doctors. Quick and easy to perform on a small ‘one-off’ stoolsample, this is a sensive and specific non-invasive test which facilitates the idenficaon ofthose who require further invesgaon for colorectal cancer, polyps or other significantgastrointesnal diseases.Focus 2011 | Exhibion | snippets@Focus13.30-13.45 AB Sciex UK LtdW5: Liquid chromatography-tandem mass spectrometry soluonsfor steroid analysisDan Leigh, Senior Applicaon Specialist31

32Thursday 26th May11.25-11.40 Agilent TechnologiesTh2: Agilent Technologies Clinical Applicaons Including1,25-Dihydroxyvitamin D 3 and D 2Peter Christensen/Ashley SageAgilent Technologies has a range of clinical applicaons covering the analysis ofImmunosuppressants, corsol, 25-OH Vit D 2 /D 3 , metanephrine, methylmalonic acid,homocysteine, drugs of abuse and THC. Using the new Agilent 6490 Triple Quadrupoleinstrument, a method has been developed for the quanficaon of 1,25-Dihydroxyvitamin D 3and D 2 down to 10 pg/ml in plasma/serum. We will discuss what Agilent has to offer inregards to clinical analysis in terms of LC-MS instrumentaon and clinical methods.12.40-12.55 The Binding SiteTh3: Introducon to heavy-light chain (Hevylite) assays and theirclinical applicaonsAlison Levoguer, Scienfic Affairs Manager, The Binding SiteThis talk will focus on the development, analycal validaon and inial clinical datapublished on the novel IgG, IgA and IgM heavy-light chain assays.Focus 2011 | Exhibion | snippets@Focus13.30-13.45 CitySprint HealthcareTh5: Improving transparency and tracking of pathology samples and clinical trialsAndy Turner, Healthcare Director, CitySprintWith an innovave, industry-leading tracking technology, designed to ensure a secure chain ofcustody, CitySprint Healthcare delivers full transparency and traceability during the secure andmely transportaon of all your medical specimens and clinical trial drugs. Our soluon canalso opmise transportaon routes, whilst increasing security and paent care.

ACB Poster PrizesClinical Studies1 How quickly can hypoparathyroidism resolvefollowing correction of hypomagnesaemia?TJ Morris, G Horsman, Manchester2 Loss of glycaemic control in type I diabetes dueto the late development of anti-insulin antibodiesDJ Halsall, P Barker, KA Burling, R Semple,Cambridge3 When is ethylene glycol poisoning notethylene glycol poisoning?GM Frederick, N Selby, N Lawson, Derby4 Pseudohypertriglyceridaemia follow upinvestigations are essentialS Agalou, M Glynn, H Mundy, F Carragher,London5 A case of type I (distal) renal tubular acidosiswith co-existing vitamin D deficiency aspresenting features of a systemicautoimmune diseasePJ Monaghan, D Kannappan, D Darby,G Brabant, Manchester6 A rare paediatric case of familialparaganglioma in two sistersP Macdonald, L Tetlow, P Birchenough,A Kelsey, P Reed, ManchesterSponsored byAudit7 Hospital-acquired iatrogenic hypernatraemia:how big a problem?MP Cornes, C Tomkins, P Gosling,Wolverhampton8 Diagnosing diabetes in Bolton primary care:the hunt for the missing millionE Hinchliffe, AC Hutchesson, GE Wieringa,Manchester9 An audit of investigation and managementof patients with severe hyponatraemiaAS Azam, H Rickhuss, M Labib, Dudley10 Auditing NT-proBNP requesting in primarycare patients under 60JJ Scargill, Blackburn11 Systematic audit of patients with equivocaltroponin T levels using a new high-sensitivityassayS Costelloe, M Sharifi, S Mehta, M Connell,J Wells, S Sood, R Rakhit, M Thomas, D Nair,London12 The effect of introduction of a highlysensitive troponin T assay on the prevalenceof myocardial infarction in two YorkshirehospitalsW Mbagaya, D Narayanan, E Kilpatrick,P Poon, ScarboroughFocus 2011 | Posters | ACB Poster Prizes33

34Focus 2011 | Posters | TuesdayPosters TuesdayPaediatrics & IEMT1T2T3T4T5T6T7T8T9T10T11T12T13Investigating hypoglycaemia in infancy usingguidelines and packsTF Lang, DurhamA new reversed-phase LC-MS/MS cardiolipinassay for the diagnosis of Barth syndromeA Bowron, R Frost, V Powers, P Thomas,S Heales, C Steward, BristolIsolated high urinary thymine in a childundergoing anti-HIV prophylaxisR Srivastava, J Mckechnie, P Galloway, GlasgowStability of bloodspot samples forgalactosaemia screening using the Beutlertest: implementing the new PKU screeningalgorithmE Robinson, RL Jones, K McNally, P Newland,LiverpoolNewborn bloodspot result messaging pilot:a first of type projectLM Shapiro, M Tolson, P Tarn, P Richardson,LeedsPerformance of Advia 2400 vanadateoxidation method for the measurement ofdirect bilirubin in paediatric samplesunprotected from lightR Azad, K Johnson, D Robertshaw, BradfordThe importance of urine analysis in thediagnosis of metabolic disorders in two casesof unexpected death in childhoodV Powers, A Bowron, L Goldsworthy,G Haythornthwaite, G Pierre, J Stone, BristolPurine nucleoside phosphorylase deficiency:a mutation updatePL Walker, A Corrigan, M Arenas, E Escuerdo,L Fairbanks, A Marinaki, F Carragher, LondonHPRT deficiency: identification of twenty-fournovel variants including an unusual deepintronic mutationA Corrigan, PL Walker, E Escuerdo,M Arenas, L Fairbanks, A Marinaki,F Carragher, LondonEvaluation study for the GSP Neonatal IRT kitCA Dibden, S Ellin, M Downing, J Bonham,SheffieldMethod comparison of glutarylcarnitine:is there a need for a more standardisedapproach?CJ Gallagher, J Leakey, S Heales, F Carragher,R Carling, LondonUrinary reducing substances (URS) testing:time to review our practice?K Davis, K Witek, D Cregeen, M Jackson,R Carling, M Champion, F Carragher, LondonA blue baby presenting withmethaemoglobinaemiaCM Lippiatt, AM Grove, P Walker, M Jordaan,WakefieldMethodsT14T15T16T17T18T19T20T21T22T23T24T25T26T27Semi-automated reflex testing for on line SPELC-MSMS: cascade testing to eliminate 3-epi25 hydroxyvitamin D 3 interferenceM Wright, KP Taylor, DJ Halsall, CambridgeMeasurement of urinary 5-hydroxyindoleacetic acid using online solid phase extractioncoupled liquid chromatography-tandem massspectrometrySR Wickramasinghe, Z Arkir, LondonDetermination of the reference rangesof urine calcium to creatinine ratio inhealthy adultsKM Stepien, P Prinsloo, P Gupta, N Dennis,T Hitch, NottinghamEvaluation of the Abbott Architect 25-OHvitamin D assayJR Bailey, RS Chapman, M Donaldson, LondonPerformance of the Abbott Architect 25-OHvitamin D assay in DEQASJR Bailey, RS Chapman, M Donaldson, JC Jones,GD Carter, LondonProcalcitonin stability in serum and plasmaJC Clayton, LJ Wilson, JG Cunniffe,M Leonard, WirralEffect of MRM transition on 25-hydroxyvitaminD 3 and D 2 measurement by LC-MS/MSRL Shea, L Ford, JD Berg, BirminghamEvaluation of an LC-MS/MS method forsirolimus in whole bloodMM MacMahon, K Mulready, M Fitzgibbon,Dublin, IrelandA comparison of the measurement oftestosterone by two immunoassaysystemsAP Courtney, P Holloway, S Barnes, LondonThe effect of acidification of urine on calciumand phosphate measurementAP Courtney, P Holloway, S Barnes, LondonThe high sensitivity troponin T assay detectstroponin in pure water, could the assay bemade any more sensitive?J Jeffery, F Mills, V Clough, R Ayling, H Delaney,PlymouthTroubleshooting an HPLC with Coulochem,electrochemical detection assay forurine 5HIAAS Hatch, G Higgins, D Fairclough, NB Roberts,LiverpoolDeveloping a spectrophotometric method fordetecting foetal haemoglobin in stool samplesT Hitch, V Thurston, NottinghamAn evaluation of two enzyme-linkedimmunosorbent assays for the measurementof insulin-like growth factor-II in serumSJ Redding, G Wark, C Livingstone, Guildford

T28T29T30T31T32T33T34T35T36T37T38T39T40T41Simultaneous analysis of cortisol and cortisone insaliva using liquid chromatography-tandem massspectrometry with online solid phase extractionRL Jones, LJ Owen, JE Adaway, BG Keevil,ManchesterSalivary cortisol and cortisone by UPLC tandemmass spectrometry: establishing a referencerange for use in screening for Cushing’s syndromeV Powers, A Bowron, L Owen, P Thomas, BristolDevelopment of a chemiluminescentimmunoassay for chromogranin AC Searell, C Evans, I Weeks, CardiffDevelopment and validation of a LC-MS/MSmethod for the measurement of plasma reninactivity using on-line solid phase extractionS Carter, L Owen, B Keevil, ManchesterDevelopment of a high sensitivityoestradiol assayE Crouch, PooleComparison of transferrin saturationscalculated by measuring transferrin andtotal iron-binding capacityR Wigley, S Rainbow, LondonDevelopment and validation of a methodfor the measurement of chromium andcobalt in whole bloodJ Rogers, S Smith, CardiffTeicoplanin measurement by LC-MS/MS:developing a novel methodFHY Fung, JCY Tang, J Hopkins, L Bailey,A Davison, LiverpoolDevelopment of a method for measuringthiopurine S-methyltransferase activity in wholeblood using high-performance liquidchromatograpy with fluorimetric detectionSL Davies, SJ Lockhart, BG Keevil, ManchesterDevelopment and validation of a method for themeasurement of chromium and cobalt in serumJ Rogers, S Smith, CardiffDevelopment and validation of a liquidchromatography-tandem mass spectrometrymethod for the measurement of androgensin serumR Leyland, SJ Darch, M Donaldson, LondonTotal and intra-individual coefficients ofvariation for the measurement of whole bloodTPMT activityNL Barlow, V Graham, JD Berg, BirminghamFemale testosterone: are fewer discrepantresults observed post-extraction after changingfrom Siemens Centaur to the Roche CobasTESTO II immunoassay?S Mosaheb, BerkshireSimultaneous measurement of prednisolone,prednisone, cortisol and cortisone by LC-MS/MSJ Duffy, C Webster, BirminghamInstrumentationT42How significant is evaporation from samples on abiochemistry track system?KJ Hedges, JD Berg, BirminghamT43T44T45Rapid, simultaneous analysis of multiple steroidsin human serum by LC-MS/MSL Couchman, L Ghataore, RP Vincent, R Marsh,NF Taylor, LondonMarginally increasing the haemolysis index onthe Roche Modular analysers significantlyreduces the number of samples unsuitable forserum LDH and folate analysisM Livingston, JM Forsyth, DerbyEvaluation of the IDS iSYS hGH and IGF1 assaysRL Allcock, P Page, S Kaleem, MA Myers, PrestonPoint of Care TestingT46T47T48T49T50T51T52T53T54T55T56Point of care urinalysis: an examination auditF Siddique, J Tatton, E Laverick, C Ford,WolverhamptonAn early warning score system for glucoseusing Roche Inform glucose metersP Ridgwell, N Smith, D Cannon, LutonImpact of analytical performance of point of careblood glucose meters on application of a ‘tightglycaemic control’ protocol in an intensive careunit settingM Ryan, P McBride, R Calderwood, AntrimQpoint: a user friendly EQAS for bloodglucose metersKL Whiting, CamberleyA comparative evaluation of the CholestechLDX and CardioChek PA point-of-care testinglipid and glucose analysersSJ Whitehead, C Ford, R Gama, WolverhamptonA pragmatic study of the diagnosticperformance of a urine albumin-to-creatinineratio point-of-care test for use in the detectionof albuminuriaMP McTaggart, RG Newall, CP Price, PE Stevens,RG Pinnock, EJ Lamb, AshfordA false negative pregnancy test within theA&E Department using point-of-care testingJL Williams, V Lane, A Singal, JD Berg,BirminghamImplementation of data networked urine stripreaders in an emergency surgical admissions wardI Smith, D Bishop, K Paddon, J Kay, C Mevada,OxfordPatients do it at home! Home testing kits:are consumers truly informed?H Kinns, N Smith, D Housley, DB Freedman, LutonQuality of point of care urinalysis and the needfor improvementC Glicksman, F MacKenzie, S Davie, LondonInnovative POCT co-ordinator reports fromUK NEQASJ French, F MacKenzie, A Robins, BirminghamQuality AssuranceT57Development of an automatic flagging systemto identify potentially “hooked” urine albuminsamplesNJ Gilberthorpe, T Hitch, NottinghamFocus 2011 | Posters | Tuesday35

36T58Development of an external quality assessmentscheme for serum angiotensin convertingenzymeGJ Davies, MA Thomas, CardiffT75Audit of CRP requesting by the EmergencyDepartmentLJ Hikin, N Stockdale, DT Vallance, MH Labib,DudleyFocus 2011 | Posters | TuesdayT59T60T61T62AuditT63T64T65T66T67T68T69T70T71T72T73T74Impact of introduction of a zero tolerance policyon request form error rates in a DGH settingMF Ryan, M Entwistle, G Kennedy, AntrimMonitoring FOBT positivity in the nationalbowel cancer screening programmeC Burtonwood, SP Halloran, P Butler, GuildfordNon-specificity of creatinine assays probed byUK NEQAS; even glucose can interfere!F MacKenzie, BirminghamInnovative laboratory network reports fromUK NEQASF MacKenzie, J French, A Robins, BirminghamFaecal occult blood test auditA Kiley, T Everitt, Westcliff-on-SeaAnyone for TPMT? An audit of TPMTrequesting at Southend HospitalA Kiley, L Cranfield, Westcliff-on-SeaAudit of serum free light chains requestsin a District General HospitalC Soromani, P West, J Luckit, N Rabin, LondonAudit of thiopurine methyltransferaserequests in a District General HospitalC Soromani, P West, LondonA clinical audit of total parenteral nutritionsupport in University Hospital LewishamE Fung, SR Wickramasinghe, J Panteli, M Crook,LondonThe general practioners and the challenge ofhypertriglyceridaemia: the scorers, the losersand the spectatorsAM Hassan, H Griffths, P Cooney, ManchesterAppropriateness of tumour marker requestingin a district general hospitalLG Hawkins, P West, Tunbridge WellsAudit of AST and the liver function profileat the Royal Free Hampstead NHS TrustS Costelloe, M Connell, R Browne, M Thomas,LondonAudit of CK-MB requesting and clinical useat the Royal Free Hampstead NHS TrustS Costelloe, M Connell, J Wells, M Thomas,LondonAn audit of requests for the oral glucosetolerance test in a district general hospitalPS West, LondonAn audit of requests for androstendione anddehydroepiandrosterone sulphate in a DistrictGeneral HospitalPS West, J Emmanuel, H Kuhan, LondonThe utility of plasma metanephrinemeasurement in the detection ofphaeochromocytomaA Abdel-Razik, P Reed, MF Stewart, ManchesterT76T77T78T79T80T81T82T83T84T85T86T87T88T89T90Audit of oral glucose tolerance tests inprimary careO Clifford-Mobley, N Sawyer, F Riddoch,S Davie, London“Add-on” test requests: are samples storedon sample manager modules suitable fordelayed analysis?RL Kift, SR Goodall, LeedsManaging demand for thyroid function tests:a re-auditMC Davies, CreweTransport of samples by pneumatic tubedoes not significantly increase the tendencyfor haemolysisC Treslove, M Guy, SalfordToo much of a good thing? An audit ofinappropriate phlebotomy at AintreeSL Hanton, CA Chadwick, A Wootton, LiverpoolAudit of criteria used in haemochromatosisgenotype testingTJ Morris, G Horsman, ManchesterImplementing cascade screening for familialhypercholesterolaemia in times of austerity:an audit of current practiceTJ Morris, G Horsman, ManchesterAudit of NT-proBNP requesting in Hull andEast YorkshireCL Rigg, K Smith, I Hanning, HullAn audit of the clinical incidents occurring withinthe Department of Clinical Biochemistry at EastKent Hospitals University NHS Foundation TrustMP McTaggart, SL Stock, AshfordAn audit of impaired glucose regulationmonitoring following an oral glucosetolerance testM Sargazi, WD Neithrcut, WirralDemand management of GI tumourmarkers (CEA and CA19-9) requestsL Tibi, L Calonzo, I Chandarana, S Catnach,Hemel HempsteadAll-Wales audit of method-dependent TSH assaybias and use of TSH decision limits for guidingtreatment of subclinical hypothyroidism asdefined by ACB/BTA thyroid guidelines (2006)KL Parham, DH Ducroq, MA Thomas, C Evans,CardiffThe use of educational comments in limitinginappropriate tumour marker requestsE Moody, D Powell, A Rudenski, ManchesterAn audit of the appropriateness of primaryand secondary care vitamin D requestingFA Davidson, A Day, Weston-super-MareAudit of paediatric methotrexate requestsMay 2009 - April 2010 to determine expectedresults patternsA Sarker, A Gidman, A Park, Cambridge

T91T92T93T94The effect of local guidelines on tumour markerrequesting: a retrospective auditR Leyland, N Martin, N James, D Wickens,P Leonard, LondonSerum uric acid: an overlooked co-morbiditymarker in the assessment of patients forbariatric surgeryK Stuart, A Abeysekera, M Labib, DudleyAn audit of the use of tumour markers againstnational, local and laboratory guidelinesRS George, J Wassell, R Goodall, BristolMeasurement of chromogranin B haslimited clinical utility for monitoring patientswith NETs: a 3 year retrospective audit in atertiary referral centrePJ Monaghan, JW Valle, W Mansoor, PJ Trainer,D Darbym, ManchesterT95T96T97T98Is venepuncture technique a contributory factorin high rates of A&E sample haemolysis?AM Parasram, A Everitt, T Hogan, L Abdullam,BasildonThe clinical significance of low alkalinephosphatase results in adults and childrenand the suitability of current reference rangesP Mohammed, A Wall, JD Berg, BirminghamHospital in-patients with hyponatraemia:could we do better?AS Davison, C Iqbal, T Purewal, E Marks,LiverpoolAudit of the short synacthen testKK Chatha, C Webster, BirminghamFocus 2011 | Posters | Tuesday37

38Posters WednesdayFocus 2011 | Posters | WednesdayBone Disease & Calcium MetabolismW1W2W3W4W5Repeat requesting of 25-hydroxyvitamin Din a UK District General HospitalT Teal, R Travers, WinchesterBiochemical effectiveness of a high doseoral vitamin D supplementation protocol®for treating hypovitaminosis DRP Vincent, MO Elnenaei, D Shipnaugh,R Chandra, C Moniz, LondonClinical relevance of serum total25-hydroxyvitamin D as measured by twoimmunoassays and TurboFlow TM LC-MS/MSL Couchman, R Musto, RP Vincent, R Clarke,R Langworthy, C Moniz, LondonVitamin D and antiepileptic treatmentsR Patle, R Inaoui, L Nashef, C Moniz, LondonEffects of vitamins D 2 and D 3 on osteoblastdifferentiation and activityF Lam, A Zarei, D Mahoney, G Mabilleau,A Sabokbar, A Morovat, OxfordCardiovsacularW6W7W8W9W10W11W12W13A study of insulin-like growth factor bindingprotein-2 as a marker of insulin sensitivity inSaudi and Caucasian subjectsMRR Self, G Wark, A Borai, S Shafi, G Ferns,C Livingstone, FrimleyAn audit of serial high-sensitivity troponin Tmeasurements for early diagnosis of myocardialinfarction in the Emergency DepartmentJL Waldron, C Webster, J Alan, BirminghamA comparison of biochemical markers forcardiovascular risk in Southern Asians andNorthern Europeans based in the UKH Sawney, D Gaze, P Collinson, LondonThe effect of fibrate treatment forhyperlipidaemia on serum creatinine andcystatin CV Ncube, B Starkey, T Wang, FrimleyFirst-line screening for heart failure withbrain natriuretic peptide: a costly strategy?A Rudenski, J Scargill, P Woolfson,M Guy, SalfordClinical impact of using the troponin I 99thpercentile cut-off for diagnosis of acutecoronary syndromeS Zouwail, M Wasik, G Davies, CardiffA rare case of tendon xanthomataM Balasubramani, C Dawson, K Crudgington,G Bayly, BristolGenotype-phenotype correlation in familialhypercholesterolaemia: a snapshot from theSouth West of EnglandM Balasubramani, L Yarram, M Williams,S Humphries, G Bayly, BristolW14W15W16W17Investigation of the incidence of macrotroponin-Tin the Roche high sensitive troponin-T assayL Hawke, N Lawson, J Forsyth, L Clark, DerbyTrends in the specialist referrals and treatmentof familial hypercholesterolaemiaMJ Turzyniecka, TA Gray, SheffieldImplementation and use of the highlysensitive troponin T assayK Smith, DJ Andrews, R Cramb, BirminghamBiochemical changes associated with weightloss in obese subjectsM Ryan, DC Flanagan, C Torrens, DO Finnegan,ColeraineDiabetesW18 Combination of HbA1c and blood glucoseimproves diagnosis of diabetes mellitusM Ryan, R Nicholl, R Calderwood, AntrimW19 12-year audit of metabolic and glycaemiccontrol in a DGH out-patient diabeticpopulation against primary care QoFstandards of careM Ryan, S Kassim, LK Diong, ColeraineW20 Variant haemoglobins identified whenasymmetrical peaks produced by IE HPLC forHbA1cSE Manley, CL Mason, RA Round, BN Green,P Narendran, R Cramb, BirminghamW21 Rare, ‘fast’ haemoglobin variants detected byhigh performance liquid chromatographyanalysis performed for HbA1c measurementS Misra, MR Hancock, LondonW22 Urinary bile acids are increased in type 2diabetes mellitusD Taylor, J Alaghband-Zadeh, R Sherwood,L Alexander, C Stone, C Moniz, C le Roux, LondonW23 Glycated haemoglobin: a reliable marker ofinsulin resistance in subjects with normalglucose toleranceAA Borai, C Livingstone, G Ferns, Jeddah,Saudi ArabiaW24 Insulin sensitivity (HOMA-S) predicts HbA1Creduction with a GLP-1 analogueAH Heald, RP Narayanan, D Lowes, E Jarman,SG Anderson, D Oleesky, M Davies, MZ Qureshi,CreweW25 Use of fasting glucose concentrations inantenatal glucose tolerance testsC Glicksman, T Brooker, F Riddoch, S Davie,D Simms, LondonW26 Are clinicians ready for the transition to soleIFCC reporting of HbA1c?B Jones, C Meek, G Ball, LondonW27 Lipid monitoring in diabetes: failure to requesta full lipid profile is resulting in inaccuratemonitoring in relation to the NICE clinicalguideline targetS Hultin, AP Day, Weston-super-Mare

W28W29W30W31The use of serum C-peptide levels for theclassification of diabetes mellitusSJ Redding, G Wark, C Livingstone, GuildfordConsiderations for safe and effective use ofglycated haemoglobin in the management ofpatients with diabetes mellitusD Church, DJ Halsall, D Simmons, CambridgeInappropriate pathology testing: using diabetesas a model to assess prevalence, impact ofnational guidance and practice-to-practicevariabilityOJ Driskell, D Holland, FW Hanna, PW Jones,J Pemberton, M Tran, AA Fryer, Stoke-on-TrentOral glucose tolerance tests: are biochemistrylabs setting the best example?DM Kennedy, L Jerrom, C Pitt, BirminghamEndocrinologyW32W33W34W35W36W37W38W39W40W41Cushings with a catchS Mapplebeck, K Metcalf, C Corns, SouthendThe relationship between serum TSH andfree T4 in the elderlyPM Clark, R Holder, S Haque, R Hobbs,LM Roberts, JA Franklyn, Birmingham ElderlyThyroid Study Team, BirminghamSignificant hypertestosteronaemia with alack of virilisation in a female patient withchronic liver diseaseH Divyateja, V Thurston, NJ Gilberthorpe,S Page, N Taylor, T Hitch, NottinghamSynthetic macroprolactin: characterizationof a human serum based prolactin-mousemonoclonal antibody complexDJ Halsall, SJ Oddy, K Gordon, AR Ellis,M Fahie-Wilson, PM Clark, CambridgeShould SHBG be measured routinely in theinvestigation of female hyperandrogenaemia?K Smith, J Shepherd, E Kilpatrick, HullMorbidity and mortality of infants with saltwasting congenital adrenal hyperplasia in anunscreened populationBE Hird, L Tetlow, L Patel, S Tobi, P Clayton,ManchesterThe biological variation of IGF-1 in stableacromegalySJ Glover, R Murray, SN Mohammad, JH Barth,LeedsClinical performance of the Roche Cobas e411automated assay system for TSH-receptorantibodies for the diagnosis of Graves’ diseaseNR Syme, AD Toft, M Stoddart, GJ Beckett,EdinburghMethod-specific normal cortisol responseto the short Synacthen testN El-Farhan, A Pickett, D Ducroq, K Parham,C Bailey, A Armston, N Morgan, DA Rees,C Evans, CardiffA rare case of hyperandrogenism in afemale phenotypeH Divyateja, N Greig, S Page, T Hitch,NottinghamW42W43W44W45W46W47W48W49W50W51W52W53W54GutW55W56Revision of androgen reporting limits atSalford Royal HospitalD Turnock, J Kane, A Rudenski, SalfordCushing’s disease in a three year old girl:the case of the missing tumourE Robinson, P Dharmaraj, J Blair, P Newland,LiverpoolSimultaneous analysis of steroid panel inhuman serum by LC-MS/MS: comparison withimmunoassayL Ghataore, L Couchman, RP Vincent, R Marsh,C Moniz, NF Taylor, LondonFirst trimester reference ranges for thyroidfunction testsLK Stokoe, SD Troup, S Razvi, GatesheadThe ratio of LH to FSH measured in womenwith hyperandrogenaemia is dependent onthe analytical platform usedM Gotseva, M Davies, A Cooper, P Byrne,D Oleesky, A Heald, I Laing, CreweMacroprolactin: validation of the PEG precipitationassay and a survey of 18 months in practiceNJ Rankin, S Zaman, AA Fryer, Stoke-on-TrentPrevalence of congenital hypothyroidism ininfants presenting with prolonged jaundiceFM Ivison, S Gopalkothandapani, I Banerjee,L Tetlow, ManchesterClinical significance of low testosterone valuesin men aged 20 to 50 years oldG Dodds, J Shepherd, D Narayanan, HullUrine steroid profiling in pituitary and adrenalCushing’s syndromeRP Vincent, J Alaghband-Zadeh, CW le Roux,C Moniz, KM Schulte, SJ Aylwin, NF Taylor, LondonA dose-dependent interference in theimmunoassay of serum cortisol by the11β-hydroxylase inhibitor metyraponePJ Monaghan, LJ Owen, PJ Trainer, G Brabant,BG Keevil, D Darby, ManchesterPrimary autoimmune thyroid disease withisolated secondary adrenal deficiency andhigh background autoimmunity: an unusualcombinationH Sharma, M Sharma, S Bulusu, LondonAntiretroviral drugs and biochemistry tests:need for caution when interpreting resultsSS Min, S Bulusu, LondonDetermining calculated free testosteronereference ranges in an adult male normalpopulation using the Roche E170 testosteroneII methodS Haslam, N Hunt, M Myers, PrestonReview of clinical utility of alpha-1-antitrypsin,serum copper, alpha-foetoprotein andcaeruloplasmin components of ‘liver screen’testing from the gastroenterology service in a DGHM Ryan, A Varghese, ColeraineA clinical evaluation of a new point of caretesting device for faecal calprotectinJ Wassell, M Wallage, E Brewer, BristolFocus 2011 | Posters | Wednesday39

40Focus 2011 | Posters | WednesdayW57W58W59W60W61W62An audit of the pattern of test requestsfor tissue transglutaminase antibodiesA Gbegbaje, P Bourne, CreweFaecal inflammatory markers in childrenwith Crohn’s diseaseCP Glenn, AE Wiskin, F Majid, RM Beattie,SA Wootton, SouthamptonProton pump inhibitors and hypomagnesaemia:a case for PPI inhibiting magnesium absorptionfrom GI tractI Bailey, BromleyCalprotectin and inflammatory bowel diseases:Isle of Wight experienceA Al-Bahrani, L Grellier, C Sheen, C Tracey,A Domanski, Newport, Isle of WightA service evaluation of faecal sugarchromatographyJD Spencer, MJ Henderson, LeedsComparison of the diagnostic performance oftransient elastography and non-invasive fibrosisscoring systems in patients with biopsy provennon-alcoholic fatty liver diseaseI Barnova, BH Lopez, R Przemioslo, LondonNutritionW63Changes in asymmetric dimethyl arginineand nitric oxide post-bariatric surgeryR Patle, S Dubb, J Alaghband-Zadeh,R Sherwood, F Tam, A Frankel, M Bueter,CW le Roux, LondonAcute MedicineW64W65LipidsW66W67W68W69W70Atypical presentation of myocardial tuberculosisKM Stepien, NottinghamAn audit of the outcome of severehypernatraemia in hospitalised patientsA Sanders, D Vallance, M Labib, DudleyThe evaluation of population characteristicsin a patient cohort attending a routinespecialised lipid clinic at a university hospitalKM Stepien, H Divyateja, P Prinsloo, P Gupta,NottinghamInherited hypercholesterolemia due to combinedLDLR mutation and FDB mutation leading topremature coronary artery disease in a young manD Chandrajay, A Waise, YorkStandards for lipid analysis and reporting:can we achieve a consensus?SJ Pattman, RDG Neely, Newcastle-upon-TyneA study to establish factors associated withfibrate induced elevation in creatinineA Abbas, J Raju, S Ramachandran, S Saraf,S Ramachandran, Sutton ColdfieldSignificant increase in HDL cholesterol isassociated with low pre-treatment HDLcholesterol following fibrate therapyS Saraf, J Raju, A Abbas, A Jones,S Ramachandran, Sutton ColdfieldW71W72W73Effect of historical changes in HDL-cholesterolmeasurements on cardiovascular risk assessmentR Marrington, C Webster, C Jewkes, WA Bartlett,A Jones, BirminghamThe role of lipoprotein (a) in clinicalbiochemistry laboratoriesR Marrington, C Webster, C Jewkes, A Jones,BirminghamAre our HDL-C methods fit for purpose?R Marrington, J French, C Webster, C Jewkes,WA Bartlett, A Jones, BirminghamOncologyW74W75W76W77A survey of users of an SAS thyroglobulin serviceK Gordon, BirminghamElevated amylase in a patient with IgA-kmyelomM Sargazi, N Butt, M Leonard, WirralPancreatic cyst fluid CA19-9; a usefulinvestigation?R Langworthy, A Gera, J Devlin, R Sherwood,LondonInterference in PSA immunoassaysD Church, P Barker, KP Taylor, DJ Halsall,CambridgeHaematologyW78W79People, places and parasites:over 30 years of malaria investigationKL Williams, C Taylor, J Myburgh, GillinghamHow well do we manage newly diagnosedmyeloma and MGUS patients?:a 12 month audit of patient follow-upP Mohammed, L Hackett, Y Shakil, A Wall,JD Berg, BirminghamClinical StudiesW80 Evidence of caffeine abuse in at-riskpopulationsKJ Hedges, JD Berg, BirminghamW81 Evaluation of a kisspeptin assay as a screeningtool for pre-eclampsiaJJ Logie, SC Riley, FC Denison, JE Norman,RM Reynolds, WishawW82 Self referral for health-related problemsassociated with alcohol misuse in BirminghamP Kampanis, E Furlong, G Georgiou, A Wall,J Berg, BirminghamW83 The management of ethylene glycol poisoningon a general paediatric wardG Hann, D Duncan, D Sohi, P West, LondonW84 Tragedy strikes twice: two cases of long chain 3hydroxyl acyl coenzyme A dehydrogenasedeficiency occuring in the same familyP West, T Bycroft, V Jones, LondonW85 Defining suitable reference intervals forcreatinine, thyroid stimulating hormone,free thyroxine and urate in pregnancyB Shine, S French, M Mirzazadeh, T James,I Smith, L MacKillop, JD Kay, Oxford

Posters ThursdayRenal DiseaseTh1Th2Th3Th4Th5Th6Th7Th8Th9Th10Th11Th12Serum levels of troponin I in patients withrenal failureF Stratford, Y-Q Wong, T James, R Morovat,B Shine, OxfordAcute kidney injury with tubulointerstitialnephritis and excess oxalate crystals:how toxic is vitamin C and sclerotherapy?KM Stepien, R Sims, T Hitch, P Prinsloo,NottinghamA study into the biological variation ofbone-specific alkaline phosphatase activityamongst stable haemodialysis patientsS Sardiwal, PE Stevens, MP Delaney, EJ Lamb,CanterburyComparability of CKD-EPI and MDRDequations in a large UK cohort: what is theimpact of age?JL Carter, PE Stevens, J Irving, EJ Lamb,CanterburyHigh sensitivity troponin T concentrationsincrease as renal function declines and aresignificantly affected by haemodialysisGC McKeeman, M McDonnell, P Archbold,G Connolly, B Roberts, E Hanna, D Fogarty,BelfastA comparison of ACR and PCR measurementin the detection of proteinuriaMP McTaggart, RG Newall, CP Price,PE Stevens, RG Pinnock, EJ Lamb, AshfordIntroduction of iohexol glomerular filtrationrate into paediatric clinical practiceK Mitchell, R Hitchcock, C Mevada, J Taylor,J Craze, T James, OxfordHow well is acute kidney injury identifiedin an acute general hospital?ID Watson, A Fazleen, SouthportAcute kidney injury: real-time identificationand monitoring using APEX iLabJ Monaghan, B Rai, N Selby, L Crowley, R Fluck,N Lawson, DerbyVerification of the urinary neutrophilgelatinase-associated lipocalin assayperformance on the Abbott ARCHITECTi1000srR Cullen, M Fitzgibbon, Dublin, IrelandThe effects of goal directed therapy on kidneyinjury as measured by urine neutrophilgelatinase-associated lipocalin in patientspost-major abdominal surgeryR Cullen, S Jhanji, R Pearse, M Fitzgibbon,Dublin, IrelandAccuracy of the MDRD and CKD-EPIGFR-estimating equations in older peopleEJ Lamb, H Kilbride, G Eaglestone, S Knight,MP Delaney, CK Farmer, SE O'Riordan, RN Dalton,PE Stevens, CanterburyTh13Th14Th15Th16Method differences in parathyroid hormoneconcentrations in patients with chronic renalfailure: implications for patient care and aninterim solutionA Ellis, S Walker, A Almond, EdinburghAutomated ammonia assay: evaluation andapplication to investigate whether ammonialevels are influenced by kidney functionS Nundlall, A Milan, S Philips, L Bailey, M Howse,N Roberts, LiverpoolEffects of changing from the modification of dietin renal disease equation to the chronic kidneydisease epidemiology collaboration equation onthe classification of patients into the differentstages of chronic kidney diseaseB Shine, CA O’Callaghan, DS Lasserson, OxfordeGFR: what next?OJ Driskell, FW Hanna, AA Fryer, Stoke-on-TrentProteins/EnzymesTh17Th18Th19Th20Th21Th22Th23Th24Cryoglobulin requesting at Southend HospitalNHS TrustS Mapplebeck, SouthendGlycosylation of IgG paraproteins:a potential marker of malignancyJA Schroeder, S Fleming, RedditchCryofibrinogen: clinical and analytical aspectsH Sharrod, M Saas, H Barbour, SouthamptonAn audit of the electrophoresis commentsreported across the Essex Chemical PathologyNetwork laboratoriesSK Moore, AS Everitt, G Brindle, EssexThe impact of the introduction of the SebiaCapillarys2 on the number of serum proteinelectrophoresis samples selected forimmunofixationJM Armer, D Paisley, JE Hogg, GlasgowManipulation of the active site of humanglycolate oxidase to assess the role of long-chainhydroxy-acid oxidase in glyoxylate metabolismN Unsworth, G Rumsby, EL Williams, LondonCan you add to your service byimmunosubtraction?JM Armer, D Paisley, JE Hogg, GlasgowStability of whole blood TPMT enzyme activityunder conditions experienced during transitNL Barlow, V Graham, R Shadra, JD Berg,BirminghamToxicology/TDMTh25Th26Colloidal silver and catatonic schizophreniachickenor egg?KM Stepien, S Brown, NottinghamLead poisoning of unknown causeKM Stepien, P Morris, S Brown, L Morgan,S Page, NottinghamFocus 2011 | Posters | Thursday41

42Th27Th28Th29Th30Development of a liquid chromatographytandem mass spectrometry method tomeasure a profile of 7 anti-epileptic drugsKJ Duxbury, CA Chadwick, LiverpoolStability of routinely measured therapeuticdrugs in the BD SST II Advance vacutainer®N Greig, L Morgan, S Brown, NottinghamDevelopment of an enhanced LC-MS/MSmethod for the detection of 14 differentbenzodiazepines and comparison with twocommercial immunoassaysC Mahoney, G Waite, SalfordAssessment of Oracol+ oral fluid collectiondevices for measuring salivary drugs of abuseusing aqueous and saliva standard curvesRL Shea, S George, JD Berg, BirminghamSimultaneous measurement of cyclosporinand tacrolimus from dried blood spots byLC-MS/MSE Hinchliffe, JE Adaway, LJ Owen, BG Keevil,ManchesterMeasurement of antipsychotic drugs inchildren and adolescents: oral fluid, capillaryblood, and dried blood spotsSJ Partridge, DS Fisher, RJ Flanagan, LondonTowards a microextraction method forsalivary drugs of abuse measurementby GCMSRL Shea, S George, JD Berg, BirminghamDevelopment and validation of an ICP-MSmethod for lithium blood spot analysisP Kampanis, K Hedges, TMT Sheehan,JD Berg, BirminghamEvaluation of different methods for carryingout unknown drugs screens in urineE Moody, G Waite, ManchesterDrug detection in oral fluids versus urine:what are the differences?H Mendoza, G Lauder, D Ajeda, B Kidd,WA Bartlett, DundeeTaking a snapshot of occupationaldrug screeningSA George, BirminghamThe changing pattern of drug use in theWest MidlandsSA George, BirminghamThe detection of antidepressant treatmentsin poisoning casesSA George, BirminghamAre paracetamol and salicylate requestsappropriate?HM Jopling, C Reeves, A Jones, GJ Ayers,ManchesterTurboFlow TM technology for the therapeuticdrug monitoring of azole antifungal drugsS Buckner, L Couchman, C Moniz, MM Ceesay,A Pagliuca, RJ Flanagan, LondonValidation of serum separator tubes forantibiotic measurement on Roche IntegraLE Clark, J Johnston, J Forsyth, DerbyTh43Th44Th45Development of an automated MS-basedscreening procedure for clinical and forensictoxicologyJ Kempf, S Vogt, B Saar, J Hillis, B Schneider,S Götz, Freiburg, GermanyDevelopment of a LC-MS/MS method tomeasure the legal high cathinone and itsderivatives in the clinical laboratoryJ Reeve, I Clunie, L McKay, J Allison,D Stephen, AberdeenDevelopment of a LC-MS/MS methodto measure the new psychoactive legalhigh methylenedioxy-2-aminoindane inthe clinical laboratoryJ Reeve, I Clunie, L McKay, J Allison,D Stephen, AberdeenFocus 2011 | Posters | ThursdayTh31Th32Th33Th34Th35Th36Th37Th38Th39Th40Th41Th42Trace ElementsTh46Th47Th48Serum trace elements concentrations afterbariatric surgeryDK Papamargaritis, ET Aasheim, B Sampson,CW le Roux, LondonTechnical evaluation of a rapid combinedmethod for copper, zinc and selenium inserum and urine by ICPMSO Clifford-Mobley, S Whiting, LondonTissue copper concentrations in paediatricnon-alcoholic fatty liver diseaseK Raja, E Fitzpatrick, A Dhawan, A Bomford,LondonMolecular GeneticsTh49Th50Th51Th52Th53Th54Single nucleotide polymorphisms in thetyrosinase gene and their association with therisk of and severity of multiple sclerosisNJ Rankin, RC Strange, AA Fryer,Stoke-on-TrentPolymorphisms of the glucocorticoid receptorgene and postnatal depressionL Darwin, N Engineer, N Deole,D Grammatopoulos, CoventryA patient with the rare alpha-1-antitrypsinvariant Zbristol in compound heterozygositywith the Z mutationKJ Bates, M Hill, N Kalsheker, A Barlow, B Clark,RA Sherwood, LondonMutation screening in suspected familialhypercholesterolaemia in MerseysideSL Hanton, C van Heyningen, DB Wile,R Mountford, LiverpoolA simple and rapid method of genotypinga common variant in the FTO gene thatpredisposes to childhood and adult obesityJP Smith, A Shoukry, D Vallance,M Labib, DudleyDevelopment of an assay for the geneticdiagnosis of 17β-hydroxysteroid dehydrogenasetype 3 deficiencyG Esmaeil Pourmahram, E Williams, G Rumsby,Hertfordshire

Th55Th56Real-time PCR genotyping of four SNPsassociated with warfarin sensitivity and theirfrequency in an anticoagulated patient groupFA Davidson, R Goodall, BristolComparison of eight pharmacogeneticalgorithms for the prediction of warfarin doseFA Davidson, R Goodall, BristolManagementTh57Th58Th59Th60Th61Th62Th63Th64Th65Th66Sample centrifugation in primary careH Turner, K McCurrach, I Philip, J Allison,AberdeenTackling demand management with adouble-edged sword: successful pilot of‘vetting’ referred-out testsC Tomkins, C Darby, SCH Smith, CoventryCritical appraisal: a simple tool to improveefficiency in the laboratory and help meetthe QIPP challengeR Carling, S Agalou, A Booth, C Gallagher,M Jones, K Witek, F Carragher, LondonEstablishment of an automatedcommenting system in a communitypathology laboratoryG Smith, K Williams, JL Barron, C Ng,Christchurch, New ZealandSelf-testing by general practitioners:how extensive is it?JL Williams, JD Berg, BirminghamImplementing operations performancemanagement system within the laboratoryK Witek, A Corrigan, S Carney, P Clements,R Carling, F Carragher, LondonVitamin D: results of an individualisedapproach to demand managementC Tomkins, J Hawley, CoventryExcessive blood taking: enough is enoughJL Williams, RK Shardra, JE Berg, BirminghamTelephoning results: a view from theother sideJL Williams, JD Berg, BirminghamIntroduction of electronic requesting anddemand management into the EmergencyDepartment: does it work?C Webster, A MacNamara, R Boddy, D Husband,P Dyer, A Jones, BirminghamTh70Th71Th72Th73Th74Th75Th76Th77Th78Th79Th80Th81Th82Recognising macro-TSH: a rare cause ofinappropriately high TSH valuesEJ Lewis, R Lim, F Joseph, D Ewins, N Goenka,SA Bowles, SA Faye, G Kertesz, ChesterElevated ketones and ketone bodies in diabeticketoacidosis: don’t mind the gap!TJ Morris, MA Al-Jubouri, G Horsman,ManchesterA rare cause of raised alkaline phosphataseactivityMP McTaggart, D Lawrence, C Rawson,M Saeed, L Miller, EM Kearney, AshfordCA125 unsolved: an interpretative dilemmaSD Harris, CM Sturgeon, AM Wayte, BangorThyroid function tests are not immune tomisinterpretationFM Brandie, F Jenkinson, DundeeA case of newly developed heterophileantibodies to the DiaSorin Liaison25-hydroxyvitamin D assayR Edwards, E Woolman, LondonA case of blue feetJD Spencer, J Walter, C Stainforth,MJ Henderson, LeedsSevere reactive hypoglycaemiafollowing a glucose tolerance test:a cautionary taleS Haslam, M Myers, PrestonRhabdomyolysis due to drug interactionbetween simvastatin and sodium fucidatein two patientsRL Allcock, J Malley, SM Rajbhandari,MA Myers, PrestonSpuriously raised serum creatinineassociated with an excipient present in anIV dexamethasone formulationD Darby, J So, J Russell, PJ Monaghan,ManchesterCase report: investigating a rare case ofhypoparathyroidismS Nundlall, P Ivanov, WD Fraser, LiverpoolDiagnosis and management of toxic alcoholpoisoning: experience of four casesTJ Morris, G Horsman, ManchesterAntiretroviral drugs and biochemistry testsSS Min, S Bulusu, LondonFocus 2011 | Posters | ThursdayCase HistoriesTh67Th68Th69Idiopathic hypercalcaemia in pregnancyFC Riddoch, DM Simms, MW Spring,Kingston-upon-ThamesA case of hepatocerebral mtDNA depletionsyndrome due to mutations in MPV17RL Jones, P Newland, A Morris, LiverpoolKeep your eyes open for the unusual!A hyperandrogenised 15 year old girl andthe role of the clinical biochemistC Tomkins, JW Honour, I Phillips, E Helm,H Stirling, CoventryMiscellaneousTh83Th84Th85Sodium citrate contamination:how to recognise itMP Cornes, C Ford, R Gama, WolverhamptonShort-term interventions on wards failto reduce pre-analytical errors:results of a prospective controlled trialCE Bird, GM Kemp, JH Barth, LeedsPatient survey: what patients expectfrom pathology?V Mishra, M Greenslade, M Cherry,A Herod, J Hemming, Salisbury43

44Th86The relationship between keeping afood diary and weight lossT Vidyaratne, M Labib, DudleyTh91A time for demand management ofCRP requestingN Hunt, M Myers, PrestonTh87Th88Th89Th90Spurious hyponatraemia due to tectonicinstabilityH Murray, G Smith, Christchurch, New ZealandBNP stability on storage: how best to handlesamples?C Wright, J Meek, R Chapman, M Donaldson,LondonDuty biochemist: a value added serviceS Robinson, C Reeves, ManchesterInstability of arginine in plasma and serumsamplesA Crampton, G Weaving, BF Rocks, BrightonTh92Th93Th94Assessment of haemolysis index of commonlymeasured analytes on the Roche Modularclinical chemistry systemP Mohammed, JD Berg, BirminghamFOB: fit for purpose?JF Doran, SwanseaNovoMix 30, Lantus and Levemircross-reactivities with the ADVIA Centaur XPinsulin assay and effects of haemolysisA Catchpole, T James, A Morovat, OxfordFocus 2011 | Posters | Thursday

46Exhibition FloorplanCateringAreaPosters3736353439383341403029Posters323142SeangCoffee PointInformaonArea27ACBKingsRoadEntranceFocus 2011 | Exhibion | Stands9876531615121713 1410 11218CateringArea191222123 24PresentaonAreaConferenceCentreEscalatorLink

Exhibition IndexCommercial PartnersParticipating CompanyC O M PA N Y S TA N D PA G EAbbott Diagnostics 21 48AB Sciex UK Ltd 12 50ACB 27 50A.D.P. Laboratory Services 10 50Agilent Technologies 8 51Alere Ltd 32 51Alpha Laboratories Ltd 16 51Anatune Ltd 6 51Bayer HealthCare 23 52Beckman Coulter UK Ltd 18 52Biotage AB 13 52Bruker UK 7 53Chromsystems Instruments and Chemicals 19 53CitySprint Healthcare 38 53Department of Health 30 53DiaSorin Ltd 40 54ELGA LabWater 14 54Helena BioSciences Europe 17 54HemoCue Ltd 5 54Immunodiagnostics Systems (IDS) Ltd 9 55Launch Diagnostics Ltd 35 55Lynx Environmental Ltd 1 -Menarini Diagnostics Ltd 11 55NHS Improvement 42 56Nova Biomedical 41 56Ortho Clinical Diagnostics 3 48PerkinElmer 39 56Roche Diagnostics Ltd 31 49ScheBo Biotech UK Ltd 29 56Sebia (UK) Ltd 24 57Siemens Healthcare Diagnostics – 49Thermo Fisher Scientific 15 57TouchPoint Medical Ltd 33 57Waters Ltd 34 58WEQAS 22 58Focus 2011 | Exhibion | IndexThe Editor and the ACB accept no responsibility for any claims made by companies in these Abstracts.47

48Commercial PartnersFocus 2011 | Exhibion | Commercial PartnersStand 21Abbott DiagnosticsPut science on your side at Focus 2011As always, Abbott Diagnostics is pleased to supportthe Association for Clinical Biochemistry as acommercial partner at its premier scientific meetingof the year.Quality clinical science is at the heart of fulfillingunmet clinical needs in many disease areas and withthis in mind science is once again at the heart ofAbbott’s presence at Focus.So, whether you attend our hosted parallel scientificsession (Cancer – Meeting The Needs of the Patient)on Wednesday 25th May, 08.45-10.45 or drop byStand 21 to find out about our latest scientificdevelopments; we very much look forward to seeingyou and discussing how Abbott can help you putscience on your side.Further information from:Carla Deakin, Abbott Diagnostics,Abbott House, Vanwall Business Park,Maidenhead, Berkshire SL6 4XFTel: 01628 644217 Fax: 01628 644205e-mail: carla.deakin@abbott.comWebsite: www.abbottdiagnostics.comStand 3Ortho Clinical DiagnosticsVITROS® is more than technology. It’s a totalsolution for meeting your operational and patientcare goals.Ortho Clinical Diagnostics (OCD) developssophisticated approaches to identifying andsatisfying the differing workload requirements of UKlaboratories. We can apply Lean methodologies toenhance workflow and eliminate waste fromlaboratory processes.Our proven technology includes the VITROS® Familyof Systems, VITROS® 5600 Integrated System,VITROS 3600® Immunoassay System and VITROS4600® Chemistry System which all link directly tothe flexible range of enGen automation modules,that meet individual laboratories needs.With the benefit of e-Connectivity technology wecan maximise your uptime by allowing our technicalteam to monitor your system online through asecure, real-time, two-way connection. Our RemoteMonitoring Centre identifies potential issues anddispatches engineers – often before you even knowthere’s a problem. The result is timely resolutionthat minimises unplanned downtime.OCD will be hosting an Industry SponsoredWorkshop on Tuesday 24th May at 10.45 entitledBlood Sciences Laboratory in the small or specialisthospital: is it a worthwhile approach?Further information from:Peter Clements, Ortho Clinical Diagnostics,Johnson & Johnson, 50-100 Holmers Farm Way,High Wycombe, Buckinghamshire HP12 4DPTel: 01494 658600 Fax: 01494 658605e-mail: ocduk@ocdgb.jnj.comWebsite: www.orthoclinical.com

Stand 31Roche Diagnostics LtdLeaders in Providing Pathology-Wide ManagedLaboratory ServicesRoche are delighted to be able to offer enhancedsupport for the ACB in 2011 with increased levels ofsponsorship for the Focus scienfic programme andlocal ACB meengs.At Focus 20011, Roche will be providing informaonon the benefits that our Managed Laboratory Servicesand scalable product porolio can bring to your Trust.We will provide a welcoming, relaxed atmospherewhere you can find out more informaon about theadvantages of a Roche partnership, and ask anyquesons you may have.For further informaon on Managed LaboratoryServices and our scalable product porolio, please visitRoche on Stand 31.Further information from:Peter Jones, Hospital IVD, Roche Ltd, CharlesAvenue, Burgess Hill, West Sussex RH15 9RYTel: 01444 256787e-mail: peter.jones@roche.comWebsite: www.roche.comDiagnosticsSiemens HealthcareDiagnosticsThe Siemens Healthcare Sector is one of the world’slargest suppliers to the healthcare industry and atrendseer in medical imaging, laboratory diagnoscs,medical informaon technology and hearing aids.Siemens offers its customers products and soluonsfor the enre range of paent care from a singlesource – from prevenon and early detecon todiagnosis and on to treatment and aercare.By opmising clinical workflows for the most commondiseases, Siemens also makes healthcare faster, beerand more cost-effecve. Siemens Healthcare employssome 48,000 employees worldwide and operatesaround the world. In fiscal year 2010 (to September30), the Sector posted revenue of 12.4 billion eurosand profit of around 750 million euros.Further information from:Ruth Powell, Siemens Healthcare Diagnostics,Newton House, Sir William Siemens Square,Frimley, Surrey GU16 8QDTel: 01276 696000 Fax: 01276 696680e-mail: ruth.powell@siemens.comWebsite: www.siemens.co.uk/diagnosticsFocus 2011 | Exhibion | Commercial Partners & Sponsor49

50Participating CompaniesFocus 2011 | Exhibion | Parcipang CompaniesStand 12AB Sciex UK LtdAB Sciex is a global leader in the development of lifescience analytical technologies that help answercomplex scientific challenges.AB Sciex provides instrumentation, software andservices that are used in a number of critical lifescience applications, including protein biomarkerresearch, disease studies, drug discovery anddevelopment, and food and environmental safety.AB Sciex is uniquely positioned to continue its globalleadership in the mass spectrometry market,building on a more than 20-year history ofinnovation.Further information from:Cheryl Goodall, AB Sciex UK Ltd,Phoenix House, Lakeside Drive, Centre Park,Warrington, Cheshire WA1 1RXTel: 01925 236060 Fax: 01925 236070e-mail: cheryl.goodall@absciex.comWebsite: www.absciex.comStand 27Association for ClinicalBiochemistry (ACB)The Association for Clinical Biochemistry would liketo welcome everybody to Focus 2011 in Harrogate,‘Focus on Change’.The Association’s stand will have a full range ofVenture publications books, CDs and journals,together with a range of AACC books availableat a discount. Orders may be placed for anyof the publications and be sent to your work orhome address, but make further savings by takingthe goods away on the day and incur no P&Pcharges. Member’s ties and pins are also available.Annals of Clinical BiochemistryOne of the world’s foremost in its field, the Annalspublishes fully refereed papers of internationalauthorship that contribute to existing knowledge inall fields of clinical biochemistry, especially thatpertaining to the understanding, diagnosis andtreatment of human disease. It also publishespapers on immunology, genetics, biotechnology,haematology, computing and management wherethey have both biochemical and clinical relevance.The 2009 Impact Factor for Annals of ClinicalBiochemistry was 1.917. If you have any questionsregarding the journal, please call at the ACB standand talk to a member of the ACB office staff.Lab Tests Online UK (LTOL)www.labtestsonline.org.ukLab Tests Online UK was first published in 2004.The site has grown exponentially and each yearreceives over 1 million visitors looking at some 4million pages. Patients and their carers will findsimple explanations and answers to their questionsabout lab tests whether they are from clinicalbiochemistry, haematology, microbiology,immunology, cytology or histopathology.The site has been endorsed by the Department ofHealth, is used by NHS Choices, cited on manyhospital Pathology websites and used by healthpolicy makers. It is described as 'the single mostauthoritative source of information aboutlaboratory tests on the web.Meet the Committee RepresentativesMembers of the ACB Executive and othercommittees that act on your behalf will be availableon the ACB stand at various times during Focus toanswer questions and provide information on anyaspect of the Associations activities and yourcareers.Officials from the Federation of Clinical Scientists(FCS) will be on hand each day to help you with anyqueries you have on agenda for change and otherwork-related issues.Labs Are VitalLabs Are Vital promotes the importance and valueof laboratory medicine to healthcare commissionersthrough a number of UK events and provides toolsfor laboratory professionals to promote their ownservice.The initiative is supported by the ACB, RCPath,IBMS, ACP and BIVDA, together with AbbottDiagnostics (www.labsarevital.co.uk).Further information from:Nic Law, ACB Administrative Office,130-132 Tooley Street, London SE1 2TUTel: 020 7403 8001 Fax: 020 7403 8006e-mail: enquiries@acb.org.ukWebsite: www.acb.org.ukStand 10A.D.P. Laboratory ServicesBringing Innovation to Point of Care Testingand Drugs of Abuse Analysis, with fully barcodedRapid Tests, facilitating traceability and patientreporting.Introducing Cliniqa Liquid QC Material, withexcellent shelf life and up to 3 months open vial

stability, covering, general chemistry, proteins,cardiac, HbA1C and urinalysis.Further information from:Greg Simpson/David Moloney, A.D.P. LaboratoryService, One Meadowbank Road, TrooperslaneIndustrial Estate, Carrickfergus, Unit 14, BullfordBusiness Campus, Kilcoole, Co. WicklowTel: 02893 366929 / 00 353 12812304Fax: 02893 366929 / 00353 12812307e-mail: adpni@advancediagnostics.ieWebsite: www.advancediagnostics.ieStand 8Agilent TechnologiesFor more than 70 years, Agilent Technologies hasbeen the world’s premier measurement company.Our singular focus on measurement helps scientistsand engineers address their toughest challengeswith precision and confidence. With the help of ourproducts and services, they are better able todeliver the breakthroughs that make a measurabledifference in the world.Key products include: Liquid and GasChromatography, Mass spectrometry, Microfluidics,Oligo library solutions and microarrays, Reagentschemistry, LC and GC Columns, Software andInformatics, Lab Automation, Nuclear magneticresonance, Vacuum technology, X-ray, atomic andmolecular spectroscopy.With the help of our products and services,scientists and engineers are better able to deliverthe breakthroughs that make a measurabledifference in the world. Researchers use Agilenttools to uncover the possible causes of cancer, heartdisease, autism and a multitude of other diseases –and to develop drugs that help treat them.Providing measurement solutions for biochemistry,the pharmaceutical industry, and the academicresearch community is the fastest growing part ofour business.Further information from:Kylie Wilson, Agilent Technologies,5500 Lakeside, Cheadle Royal Business Park,Stockport SK8 3GRTel: 0845 712 5292 Fax: 0845 600 835e-mail: customercare_uk@agilent.comWebsite: www.agilent.comAlere products and solutions are changing howhealthcare is delivered—extending diagnosis andhealth management from the lab, GP practice andhospital into people’s homes.Alere actively integrates diagnostic tools witheducation and health management solutions,making it easier than ever to personalize care. We’reconnecting patients to information. Information todiagnostic results. And diagnostic results tohealthcare providers, so they have the informationneeded to make the best decisions.Want to find out more? Visit www.alere.co.ukFurther information from:Jackie Dootson/Clare Mannion, Alere Ltd,Pepper Road, Hazel Grove, Stockport SK7 5BWTel: 0161 483 5884 Fax: 0161 483 5778e-mail: ukcustomer@alere.comWebsite: www.alere.co.ukStand 16Alpha Laboratories LtdLaboratories are facing the most stringent efficiencydrive encountered in recent times. One way toprovide your hospital with a means to decreasecosts whilst enhancing the patient’s clinical outcomeis by the use of new Biomarkers.Alpha Laboratories Ltd has a proven track record inworking with laboratories and clinicians in order toprovide these benefits by the use of FaecalCalprotectin. This assay enables the end user toeasily and confidently distinguish between IBS andIBD thereby reducing the number of colonoscopiesrequired in the UK.We have recently launched two more novelBiomarkers, Hyaluronic Acid and NeutrophilGelatinase-associated Lipocalin (NGAL) assays whichcan be analysed on routine clinical chemistryanalysers. This year Alpha Laboratories will sponsora workshop entitled “Focus on Acute Kidney Injury(AKI) with NGAL & Liver Fibrosis with HyaluronicAcid” which will feature two keynote speakers.Please visit us at stand 16 to discuss our products.Further information from:Alpha Laboratories Ltd, 40 Parham Drive,Eastleigh, Hampshire SO50 4NUTel: 023 8048 3000 Fax: 023 8064 3701e-mail: sales@alphalabs.co.ukWebsite: www.alphalabs.co.ukFocus 2011 | Exhibion | Parcipang CompaniesStand 32Alere LtdAlere is one of the largest diagnostic companies inthe world and employs over 850 people in the UK atmultiple locations.Stand 6Anatune LtdAnatune is a leading chromatography solutionprovider in the UK. The company has something to51

52Focus 2011 | Exhibion | Parcipang Companiesoffer all laboratories that use chromatography, butspecialises in offering solutions, products andservices to clinical, environmental, pharmaceutical,food, flavour and fragrance laboratories. Most majorbusinesses in these sectors are regular customers.Founded in 1996, the vision was to create acompany which would be more than a supplier ofChromatography equipment. Today, its philosophy isthat real customer value comes from combiningindustry, scientific and application knowledge withan emphasis on solving problems and creatingefficiency and effectiveness. The focus is on dataquality, robustness, reliability, simplicity and speed,all whilst driving down cost per sample.As a supplier of equipment from one of the world'sbest and most trusted chromatographymanufacturers, Anatune is uniquely placed tocombine the best technologies available to solveproblems.Further information from:Susan Gilbert, Anatune Ltd, Broadway House,149-151 St Neots Road, Hardwick,Cambridgeshire CB23 7QJTel: 01954 212909 Fax: 01954 212908e-mail: enquiries@anatune.co.ukWebsite: www.anatune.co.ukStand 23Bayer HealthCareBayer HealthCare is one of the world’s leading,innovative companies in the healthcare and medicalproducts industry. The company combines theglobal activities of the Animal Health, ConsumerCare, Medical Care and Pharmaceuticals divisions.Bayer HealthCare’s aim is to discover andmanufacture products that will improve human andanimal health worldwide.Bayer Healthcare has a global workforce of 53,400employees and is represented in more than 100countries.The pharmaceutical division of Bayer HealthCarefocuses its research and business activities on thefollowing areas: Diagnostic Imaging, GeneralMedicine, Haematology & Neurology, Oncology andWomen’s Healthcare. Using innovative ideas, Bayeraims to make a contribution to medical progress andstrives to improve the quality of patients’ lives.Our Men’s Health portfolio features products fortestosterone therapy and erectile dysfunction.Further information from:Bayer HealthCare, Bayer House, Strawberry Hill,Newbury, Berkshire RG14 1JATel: 01635 563000 Fax: 01635 563693e-mail: medical.information@bayer.co.ukWebsite: www.bayer.co.ukStand 18Beckman Coulter UK LtdBeckman Coulter is one of the leading providers ofin vitro diagnostic systems to hospital laboratoriesthroughout the world. We are uniquely positionedas a company with both research and diagnosticdivisions to lead the way in biomedical testing.Our focus in Harrogate will be to share with yousome of our innovative science and demonstratehow this innovation can improve the patientexperience and reduce the cost of healthcare.We look forward to seeing you at Focus 2011.Further information from:Leanne Annereau, Beckman Coulter,Oakley Court, Kingsmead Business Park,London Road, High Wycombe HP11 1JUTel: 01494 441181 Fax: 01494 429294e-mail: infouk@beckman.comWebsite: www.beckmancoulter.comStand 13Biotage ABBiotage is a global leader in life science technology.With a broad scope of tools for synthesis, work-up,purificaon, evaporaon and analysis, the companyprovides soluons and experse in the areas ofanalycal and medicinal chemistry.Biotage manufactures a range of sample preparaontools for bioanalycal, clinical, environmental, foodand forensic applicaons. With a variety of sorbentchemistries, Biotage products deliver cleanerextracts with higher analyte recovery for preciseanalysis.ISOLUTE SLE+ provides quicker, cleaner and cheaperanalysis with a simple “load, wait and elute”methodology.Addionally, EVOLUTE polymeric sorbents provide ahighly effecve soluon to the problems of ionsuppression and matrix effects from dirty extracts.These high performance sorbents allow sciensts touse a generic approach for a wide range ofcompounds, thus reducing method developmentme and allowing for clean extracts.Further information from:Ma Wheeler, Biotage AB, Kungsgatan 76,SE-753 18 Uppsala, SwedenTel: + 46 18 56 59 00 Fax: + 46 18 59 19 22e-mail: info@biotage.comWebsite: www.biotage.com

Stand 7Bruker UKBruker is a leading provider of high performanceanalycal systems whose innovave and easy to useproduct families encompass a variety of MassSpectrometers and Gas Chromatographyinstruments. Bruker ulizes LC/GC/MS based andother MS instruments (ESI-TOFs, Ion Traps, FTMS,MALDI-TOFs, single and triple quadrupole GCMS,and ICP-MS) to provide outstanding results for awide range of small molecule and protein analysisapplicaons. Delivering premium value, and backedby decades of Applicaon and Technical Supportexperse, Bruker systems enable scienstsd workingin Applied Analycal, Life Science, and the ClinicalResearch laboratories to answer even the mostchallenging analycal quesons.Further information from:James Hillis, Bruker UK, Bawner Lane,Coventry CU4 9GHTel: 0781 855 0349 Fax: 0247 646 5317e-mail: james.hillis@bruker.co.ukWebsite: www.bruker.comStand 19Chromsystems Instrumentsand ChemicalsChromsystems has revolutionised HPLC analysis forroutine diagnostics and now pioneers in developingreagent kits, calibrators and controls for tandemmass spectrometry. The company continues to setstandards for high technology solutions fordiagnostic laboratories. Optimised work flows yieldquick and reliable results.Certified products facilitate compliance withregulatory rules. The Chromsystems product rangecovers a broad spectrum of diagnostic analyses suchas therapeutic drug monitoring, vitamin profiling,newborn screening, biogenic amines, vitamin D andmore. All analyses are completely validated andready to use. Calibrators and quality controls canalso be used for HPLC and mass spectrometryanalyses independent from Chromsystems kits.An extensive service network guarantees globalavailability and service. Regular training courses addto customer success.Several products are FDA-listed. For moreinformation please visit our websitewww.chromsystems.de.Further information from:Chromsystems Instruments & Chemicals GmbH,Heimburgstrasse 3, 81243 Munich, GermanyTel: +49 89 189 30 300 Fax: +49 89 189 30 399e-mail: mailbox@chromsystems.deWebsite: www.chromsystems.deStand 38CitySprint HealthcareCitySprint Healthcare comprises a range of solutionswhich have been designed to support the healthcaresector as a whole.The specific services have been developed withextensive knowledge and experience of the medicaland pharmaceutical sectors, and provide efficient,effective transportation solutions for example forpathology, organ transplants, hospital based courierservices, logistic solutions for pharmacies andpatient home deliveries. As a leading provider ofsuch solutions, CitySprint is ideally placed to providetotal outsourced fleet solutions or flexible ad-hocsupport.CitySprint Healthcare can provide up-to-date adviceon the classification of biological and hazardousmaterial. Our dedicated team can help with allaspects of your shipping needs from planning themost efficient routes and delivering bespoke packingfor temperature controlled solutions.Our network of 31 wholly owned Service Centresacross the UK ensures that we can provide a secureand rapid response service 24 x 7 x 365.Further information from:Andrew Turner, CitySprint Healthcare,Ground Floor RedCentral, 60 High Street,Redhill, Surrey RH1 1SHTel: 0870 873 2219e-mail: aturner@citysprint.co.uk(for organisation queries hhunt@citysprint.co.uk)Website: www.citysprint.co.uk/healthcareStand 30Department of HealthThe Department of Health (DH) exists to improvethe health and wellbeing of people in England.The DH Pathology Programme is working to supportthe NHS in ensuring that pathology services are fitfor the future. The vision is for high quality andcost-effective NHS pathology services that arecommissioned according to user and patient need,are flexible enough to utilise innovative technologiesand play a crucial role in improving patientoutcomes.Visit our stand to see the latest from the Quality andProductivity Challenge (QIPP), Modernising ScientificCareers and NHS Improvement.Further information from:Daniel Gosling, Pathology Programme,Department of Health, Wellington House,133-155 Waterloo Road, London SE1 8UGTel: 020 7972 4329e-mail: pathology.modernisation@dh.gsi.gov.ukWebsite: www.dh.gov.ukFocus 2011 | Exhibion | Parcipang Companies53

54Focus 2011 | Exhibion | Parcipang CompaniesStand 40DiaSorin LtdOver the last 40 years DiaSorin has built thereputation of being a Diagnostic Specialist.We differentiate ourselves from the competitionby listening to our customers’ needs and developingproducts that meet their requirements. We alsopride ourselves on our customer focus andprofessionalism.The LIAISON® analyser offers one of the largestimmunoassay menus on a single platform, includingthe unique Direct Renin and 1-84 PTH assays as wellas the market leading Vitamin D TOTAL assay. 2011is a landmark year for DiaSorin, not only will weplace our 4000 LIAISON® system worldwide we willlaunch the LIAISON XL® our new, high throughput,random access analyser to meet the demands of themedium and large sized laboratories. To learn moreabout our product offerings and the LIAISON XL®analyser please visit us on Stand 40.From all of the DiaSorin team, we wish you anenjoyable and informative congress.Further information from:Darren Tomlinson, DiaSorin Ltd,1st Floor Richmond House, Oldbury,Bracknell RG12 8TQTel: 01344 401 430 Fax: 01344 401 431e-mail: info@diasorin.ltd.ukWebsite: www.diasorin.comStand 14ELGA LabWaterELGA LabWater MEDICA systems, designed and builtin the UK, are perfectly suited to feed the latestclinical analysers. Utilising a unique combination oftechnologies in single box systems to give CLSItype 1 water quality.• MEDICA systems deliver up to 400 litres of waterper hour, through duplexed analyser feed loops,ensuring dependability through no single point offailure.• Bacterial control, vital for Immunoassays ismaintained through recirculation of pure waterthrough RO, DI, UV and Ultra Filtrationtechnologies.• ELGA Aquaservice Managed Service Contractsprovide guaranteed running costs, giving true Riskshift from public to private sector.We have the reputation and sustainable solutions toreduce water usage, energy bills and CO 2 associatedwith heating and pumping. Our EcoBin serviceprovides a simple and safe solution for thecollection, recycling and disposal of non hazardouswastes including consumables, installation wastematerials and analyser reagent cassettes/vessels.Further information from:John Page, Elga LabWater, Marlow International,Parkway, Marlow, Buckinghamshire SL7 1YLTel: 01628 897000 Fax: 01628 897001e-mail: sales.uk@veoliawater.comWebsite: www.elgaprocesswater.co.ukStand 17Helena BioSciences EuropeWe design, manufacture and market the mostinnovave diagnosc and biomedical products forthe advancement of healthcare and medical science.Specialising in clinical electrophoresis andhaemostasis, we connue a long and establishedtradion of progress and reliability, providingclinicians and sciensts with a comprehensiveporolio of world-class instrumentaon, sowareand assays, encompassing manual and automateddiagnosc systems, and roune and specialisttesng soluons.V8: Automated Capillary Electrophoresis SystemHelena BioSciences Europe now supply the mostautomated capillary electrophoresis system,providing biomedical sciensts with an intelligent,high-throughput and mul-assay soluon integrangcapillary and gel electrophoresis.Haemostasis reagents: reliable and flexibleManufacturing a full panel of haemostasis reagents,we supply tailored soluons for an extensive rangeof leading coagulaon and haematology analysers.Superior Performance D-dimerHelena BioSciences manufacture the highest qualityD-dimer reagents in flexible kit formats, compablewith market-leading coagulometers and clinicalchemistry analysers.In addion to world-class diagnosc systems,we provide the most compeve prices onmolecular biology and ssue culture products.Further information from:Adam Stephenson, Helena BioSciences Europe,Queensway South, Team Valley Trading Estate,Gateshead, Tyne and Wear NE11 0SDTel: 0191 482 8440 Fax: 0191 482 8442e-mail: astephenson@helena-biosciences.comWebsite: www.helena-biosciences.comStand 5HemoCue LtdHemoCue focuses on the change for Diabetes Pointof Care. Visitors to the HemoCue stand will be ableto see and try for themselves the company’s full

ange of analysers and be able to test their newplatform of solutions for diabetes. HemoCue’s rangeof analysers provide the key parameter resultsneeded for top diabetes diagnostics and care.Extensively used throughout the world for screeningand diagnosing multiple conditions, HemoCue testshave been demonstrated to guarantee laboratoryprecision and accuracy in all point of care situations.With their advanced data management andconnectivity capabilities, the latest DM analysers notonly communicate with the laboratory, but can alsodownload patient results directly to patientinformation management systems.Dedicated to point of care analysis, HemoCue’ssolutions to diagnostic situations provide thelaboratory accurate answers for all healthcareprofessionals.Further information from:Anneliese Holland, HemoCue Ltd,Viking Court, Princess Road, Dronfield,Derbyshire S18 2LXTel: 0844 88 00 996e-mail: customercare@hemocue.co.ukWebsite: www.hemocue.comStand 9Immunodiagnostics Systems(IDS) LtdIDS is dedicated to the development and provisionof innovative immunoassays worldwide. Renownedfor vitamin D Tests; 25-OHD, and 1,25 (OH)2 vitaminD, IDS provides a comprehensive range of specialityimmunoassays for diagnostic and research use.IDS will be exhibiting the IDS-iSYS automatedimmunoassay system for bone, growth, cartilageand hypertension assays. The IDS-iSYS automatedimmunoassay system is well equipped toconsolidate your “send-away” testing and improveturnaround time.Please come and talk to us about our automated,co-specific 25-OH vitamin D assay, or about howthe growth assays from IDS comply with recentguidelines from the Consensus Workshop at theGrowth Hormone Research Society Meetingon hGH and IGF-I Assays (Keswick Hall, Virginia,USA).We would also be happy to discuss our completerange of automated bone markers for resorption,formation and bone turnover.An IDS industry workshop will take place in theQueen’s Suite on Wednesday 25th at 10.55 on“Clinical Application of Bone Markers”, by Prof ErikFink Eriksen MD, DMSc, University Hospital of Oslo.Further information from:James Crofts, IDS Ltd, 10 Didcot Way,Boldon Business Park, Boldon, Tyne & WearNE35 9PDTel: 0191 519 660 Fax: 0191 519 0760e-mail: james.crofts@idsplc.comWebsite: www.idsplc.comStand 35Launch Diagnostics LtdLaunch Diagnoscs are pleased to aend Focus 2011and hope that you will join us on our stand as welaunch two new ranges;Diazyme Vit D, a fully automated Elisa assay on theDS2 plaorm. Detecng D2 and D3, it providesexcellent performance and correlaon with the GC-MSreference method. Results can be obtained for 160samples within three hours.The new ARKRAY ADAMS HA-8180 HbA1c. TheHA-8180 is a fast HbA1c analyser, featuring fullautomaon and dual reporng. MEQNET link sowareallows new and exisng ARKARY instruments to beinterfaced with LIMS systems.Further information from:Pauline Boyle, Launch Diagnoscs Ltd, Ash House,New Ash Green, Longfield, Kent DA3 8JDTel: 01474 0874426 Fax: 01474 872388e-mail: paulineboyle@launchdiagnoscs.comWebsite: launchdiagnoscs.comStand 11Menarini Diagnostics LtdMenarini Diagnostics are celebrating the launch ofour latest analyser for HbA1c andHaemoglobinopathies the HB9210 and would likeyou to come and join us at Stand 11 for acelebratory drink. The analyser is the latestchapter in our 20 year history of supporting HbA1cand Haemoglobinopathy diagnosis in the UK andEurope. We will have information on the newanalyser as well as our full range of diagnosticsystems.Our staff will be pleased to answer your questionsand discuss your laboratory’s requirements.We look forward to seeing you there!Further information from:Brendan O’Dwyer, Menarini Diagnostics Ltd,Wharfedale Road, Wokingham, BerkshireRG41 5RATel: 0118 944 4100 Fax: 0118 944 4111e-mail: Brendan.odwyer@menarinidiag.co.ukWebsite: www.menarinidiag.co.ukFocus 2011 | Exhibion | Parcipang Companies55

56Focus 2011 | Exhibion | Parcipang CompaniesStand 42NHS ImprovementWorking with over 240 sites across England, NHSImprovement works with NHS organisations andclinical networks to help transform, deliver and buildsustainable improvements across the entire pathwayof care in cancer, diagnostics, heart, lung, stroke andaudiology services.With ten years practical improvement experience,NHS Improvement aims to develop sustainableeffective pathways and systems, share improvementresources and learning, increase impact and ensurevalue for money to improve the efficiency andquality of NHS services.With a focus on quality, productivity and innovation,NHS Improvement works closely with the NHSMedical board and Department of Health with allwork aligned to national priorities and supportingdelivery of key national strategies.With a continued focus on the delivery of qualityimprovements based on the latest evidence-basedpractice and a robust monitoring of performance,the work of NHS Improvement makes a significantpractical difference to services along the patientpathway and is clinically led and patient focused toachieve the best outcomes.Further information from:Iain Fletcher, Communications Director,NHS Improvement, 3rd Floor, St John’s House,East Street, Leicester LE1 6NBTel: 0116 222 5113 Fax: 0116 222 5101e-mail: iain.fletcher@improvement.nhs.ukWebsite: www.improvement.nhs.ukStand 41Nova BiomedicalThe design and manufacture of biosensors for use inPoint of Care Testing devices has been the specialityof Nova Biomedical for over 30 years. The NovaStatStrip® Glucose system provides laboratoryaccuracy in a POC setting. StatStrip® patentedmulti-well technology requires no calibration codes,has no known interferences including haematocrit,maltose, galactose, xylose, ascorbate etc and is easyto use. StatStrip® provides QC lock-out, bar-codedID, and full connectivity.Other StatStrip® meters include lactate for sepsismanagement and glucose with ketones offering themost accurate measurement of whole bloodketones for detection and management of DKA asper recent JBDS and BSPED guidelines. StatSensor-i®gives POC creatinine/eGFR results in 30 secondsoffering Radiologists, Oncologists, ICU and A&E anaccurate, reliable assessment of renal function. StatProfile® pHOx and pHOx Ultra uniquely offer acomprehensive critical care test menu including:blood gas, electrolyte, metabolite and co-oximetrymeasurements; uniquely urea, creatinine, ionisedmagnesium and total bilirubin are available on theUltra.Further information from:Linda McGough, Nova Biomedical,C3-5 Evans Business Centre, Deeside IndustrialPark, Deeside, Flintshire CH5 2JZTel: 01244 287087 Fax: 01244 287080e-mail: office@novabiomedical.co.ukWebsite: www.novabiomedical.comStand 39PerkinElmerPerkinElmer is a global company focused onimproving the health and safety of people and theirenvironment. From earlier medical insights andmore effective therapies to cleaner water and saferhomes, PerkinElmer touches the lives of millions ofpeople around the world every day.As the global leader in newborn screening andprenatal risk assessment, PerkinElmer has pioneeredthe application of tandem mass spectrometry innewborn screening. This technology enablesprograms to screen for several tens of disordersusing a single blood sample.Now, for clinical laboratories that wish to put thepower of mass spectrometry to work, the company’snew generation clinical MS/MS kits are designed tomeet present and future assay needs. The MS/MSSteroids kit supports measurement of 10 steroidanalytes in the same aliquot, while the new MS/MSVitamin D kit provides enhanced detection for25-OH-vitamin D /D3. Both assays are suitable foruse with most MSMS instruments.Further information from:Nick Withers, PerkinElmer, Chalfont Road,Seer Green, Beaconsfield HP9 2FXTel: 07876 394203e-mail: nick.withers@perkinelmer.comWebsite: www.perkinelmer.co.ukStand 29ScheBo Biotech UK LtdScheBo Biotech is proud of the scientific and clinicalevidence supporting our products. Our monoclonalantibody ScheBo Pancreatic Elastase-1 Stool Test('faecal elastase') is widely regarded as thenon-invasive “test of choice” for pancreatic exocrinefunction.

The ScheBo M2-PK Stool Test is a different approachto colorectal cancer screening. Patients with a raisedfaecal concentration of dimeric M2-PK shouldundergo further investigation (e.g. colonoscopy).This non-invasive test delivers high sensitivity andspecificity from a single small faecal sample. TheEDTA-plasma test assists with monitoring fortherapeutic efficacy, patient follow-up forrelapse/metastasis, and diagnosis in many differentcancers.Faecal lactoferrin is a dependable, economical andhighly practical biomarker of gastrointestinalinflammation. A quantitative ELISA (IBD-SCAN) anda 10-minute qualitative rapid test (IBD EZ VUE) areavailable.Ask us about the price of the tests and the evidencefor their use to differentiate Irritable BowelSyndrome (IBS) from active Inflammatory BowelDisease (IBD), to monitor therapy response and todetect disease “flares” in IBD.Further information from:Ivor Smith, ScheBo Biotech UK Ltd,POBox 6359, Basingstoke RG22 4WETel: 01256 477259 Fax: 01256-327889e-mail: i.smith@schebo.co.ukWebsite: www.schebo.co.ukStand 24Sebia (UK) LtdSebia is a world leading manufacturer of automatedelectrophoresis systems for routine and specialistbiochemistry, haematology and immunology testing.Established in 1967, Sebia continues to respond toevolving customer needs through investment in newproduct research and development. A key highlightat Focus is Capillarys 2 Flex Piercing, featuring cappiercing for sampling directly from primary tubesand a NEQAS listed method for haemoglobinopathydetection. From summer 2011, Flex Piercing willalso be available on Minicap, making it ideal forserum analysis for protein electrophoresis,immunotyping and CDT in smaller andmultidisciplinary laboratories.Also on stand, Hydrasys 2 automatically carries outall phases of electrophoresis testing. Working inconjunction with Hydrasys 2 and data acquisitionsoftware Phoresis, Sebia’s new autosampler, ASSIST,provides automation and positive sampleidentification while ensuring standardisation of allpre-analytical steps.Sebia additionally provides scientific support andprofessional training through external seminars,on-site training and electrophoresis workshops.Further information from:Chris Plows, Sebia (UK) Ltd,River Court, The Meadows Business Park,Station Approach, Blackwater, Camberley,Surrey GU17 9ABTel: 01276 600636 Fax: 01276 38827e-mail: sales@sebia.co.ukWebsite: www.sebia.co.ukStand 15Thermo Fisher ScientificThermo Fisher Scientific is a world leader in servingscience, enabling you to make the world healthier,cleaner and safer. With annual sales of more than$10 billion and 30,000 staff, we serve over 350,000customers worldwide within pharmaceutical andbiotech companies, hospitals and clinical diagnosticlabs, universities, research institutions andgovernment agencies, as well as environmental andindustrial process control settings.With two premier brands, Thermo Scientific andFisher Scientific, we help solve analytical challengesfrom routine testing to complex research anddiscovery.Thermo Scientific offers customers a complete rangeof high-end analytical instruments as well aslaboratory equipment, software, services,consumables and reagents to enable integratedlaboratory workflow solutions.Further information from:Paul Humphrey, Thermo Fisher Scientific,Boundary Way, Hemel Hempstead HP2 7GETel: 01442 233 555 Fax: 01442 233 667e-mail: analyze.uk@thermofisher.comWebsite: www.thermoscientific.comStand 33TouchPoint Medical LtdTouchPoint is a new company focused on Point of Carein the UK. The rapid shi of technology fromconvenonal instruments used in major hospitals tonow tesng at the point of paent care; we are at theforefront, and have developed an integrated POCTsystem in line with this trend in diagnoscs.Our aim is to bring new, validated and compellinganalycal technologies to laboratory sciensts andclinicians focused on providing the best point of careopons for their paents. Our technologies have beendeveloped to pioneer a new paradigm in POCT. Forexample; our new i-CHROMA system delivers resultsin 3-15 minutes aer taking the blood sample fromthe paents’ fingerp right in your laboratory or office.Focus 2011 | Exhibion | Parcipang Companies57

58Focus 2011 | Exhibion | Parcipang CompaniesOur diagnosc system is opmised for screening major“lifestyle” related diseases including, but not limited to,cardiac diseases, cancers and diabetes.Further information from:John Bolodeoku, TouchPoint Medical,Siena Court, Broadway, Maidenhead,Berkshire SL6 1NJTel: 01628 509014 Mobile: 07765 401135Fax: 01628 509100e-mail: info@touchpointmedical.comWebsite: www.touchpoint-medical.comStand 34Waters LtdWaters Corporation has 50 years history developinginnovative HPLC, mass spectrometry, software,chemistry and support services. Waters can nowprovide clinical research laboratories with completesolutions that improve accuracy and precision ofthose assays and increase productivity.The use of LC/MS/MS in clinical research laboratoriesis rapidly expanding and now includes applicationssuch as steroid analysis, homocysteine,methylmalonic acid and Vitamin D, among others.In these applications, Waters MassTrak Systems offerimproved accuracy and precision. In addition, themethods are simpler, faster and require less samplepre-treatment than the traditional LC orimmunoassay methods.Waters clinical business organisation is fullydedicated to developing groundbreaking solutionsfor diagnostic laboratories.To find out more, visit us on stand 34.Further information from:Kim Hobbs, Waters, 730-740 Centennial Court,Centennial Park, Elstree, HertfordshireWD24 7LSTel: 0208 238 6100 Fax: 0208 238 6170e-mail: uk@waters.comWebsite: www.waters.comStand 22WEQASWEQAS is one of the leading External QualityAssessment (EQA) providers with programmesdeveloped to keep abreast of technologicaladvancements and speciality areas. Our Schemes areunderpinned by commutable samples, referencemethods, informave reports, and a team ofexperienced sciensts and point of care co-ordinators.WEQAS POCT provides EQA samples to over 80% ofNHS hospitals, PCTs and pharmacies in the UK. Withthe increased volume and novel applicaons in Point ofCare Diagnoscs our vast experience in this sector canhelp you assure their safe delivery.Focus on Change – The Naonal Quality AssuranceAdvisory Panel (NQAAP) is implemenng a newstrategy on laboratory performance to ensure that thequality criteria reflects clinical use. WEQAS has takena proacve role in the support and implementaon ofthe MAPS project (Minimum Analycal PerformanceStandards) and has modified our reports to reflect thisiniave. Visit our stand to find out more about howthis affects you.Further information from:Annette Thomas, WEQAS Quality Laboratory,Unit 6 Parc Tyglas, Cardiff Business Park,Llanishen, Cardiff CF14 5DUTel: 02920 314750 Fax: 02920 314760e-mail: office@weqas.comWebsite: www.weqas.com

NotesFocus 2011 | Notes59

60NotesFocus 2011 | Notes

Our thanks to . . .The Focus 2011 Committee would like to thank all companies who havesponsored the meeting.The Commercial Partners for this meeting are:Abbott DiagnosticsOrtho Clinical DiagnosticsRoche Diagnostics LtdDiagnosticsSiemens